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Abstract 
Although new chemotherapy regimens have shown significant survival improvement in patients 
with local, locally advanced and metastatic pancreatic ductal adenocarcinoma (PDAC), 
metastasis still remains the leading cause of cancer-related mortality in this disease. Therefore, 
discovery of novel drivers of metastasis for improvement of therapeutic options against 
metastasis is of crucial importance. Patient-derived xenografts (PDX) models have become a 
promising system for studying cancer diseases. Orthotopic models have been shown to better 
mimic the metastatic disease. However, to date, only few PDX orthotopic models of pancreatic 
cancer have been reported to establish distant metastasis. The metastatic incidence in these 
models still remains relatively low, therefore development of more efficient and reproducible 
model for studying metastasis is urgently needed. 
In this thesis work, we developed several metastatic PDX models of PDAC by orthotopic 
transplantation of human pancreatic cancer specimens into immunodeficient NOD/SCID/IL2g-
receptor null (NSG) mouse. Importantly, these preclinical models develop liver and/or lung 
metastasis with a high reproducibility rate. We further used these models as an In-vivo platform 
for isolation of the human tumor populations involved in metastatic process and their functional 
and single-cell transcriptomic characterization. In-vivo transplantation of the circulating tumor 
cells (CTCs) showed that they possess high tumorigenic and metastatic potential. Single-cell 
RNA sequencing analysis revealed that the CTCs cluster separately from their matched primary 
tumor and metastatic cells, displaying low expression of cell cycle- and ECM-associated genes 
and enrichment for genes involved in ribosome biogenesis. In addition, CTCs showed an 
increased expression of numerous cancer-related genes including Survivin, AURKA, and 
AURKB among others. Moreover, Survivin protein expression was detected in primary tumors 
and metastatic lesions of all metastatic models. Pre-clinical treatment with YM155 (survivin 
suppressor) decreased the metastatic tumor burden and showed beneficial effects on survival of 
the mice bearing metastatic ortotopic tumors. In addition, primary tumor resection in 
combination with YM155 resulted in significant improvement in median survival of the mice 
compared with control group. Finally, proteomic characterization of pancreatic cancer exosomes 
isolated from primary tumors and metastatic organs of PDX models revealed an organ-specific 
protein signatures with abundant expression of human proteins some of them reported to have a 
role in metastatic organotropism.  
Spas Dimitrov Markov 
Resumen 
Aunque los nuevos regímenes de quimioterapia han demostrado una mejora significativa de la 
supervivencia en pacientes con adenocarcinoma ductal pancreático local (ADP), localmente 
avanzado y  metastásico, la metástasis sigue siendo la principal causa de mortalidad relacionada con 
esta enfermedad. Por lo tanto, el descubrimiento de nuevos ejecutores de metastasis para la mejora de 
las opciones terapéuticas contra la metástasis es de importancia crucial. Los xenoinjertos derivados 
de paciente (PDX) se han convertido en una plataforma muy prometedora para estudiar las 
enfermedades del cáncer. Se ha demostrado que los modelos ortotópicos mimetizan mejor la 
enfermedad metastásica. Sin embargo, hasta la fecha, sólo unos pocos modelos PDX ortotópicos de 
ADP se han reportado de establecer metástasis a distancia. La incidencia metastásica en estos 
modelos sigue siendo relativamente baja, por lo tanto, el desarrollo de un modelo más eficaz y 
reproducible para estudiar la  metástasis es urgentemente necesario. En este trabajo de tesis, hemos 
desarrollado varios modelos metastásicos PDX de PDAC mediante trasplantación ortotopica de 
muestras pancreáticas tumorales humanas en ratones  inmunodeficientes  NOD / SCID / IL2g-null 
receptor (NSG). Es importante destacar que estos modelos preclínicos desarrollan metástasis hepática 
y/o pulmonar con una alta tasa de reproducibilidad. Además, hemos utilizado estos modelos como 
una plataforma In-vivo para el aislamiento de las poblaciones tumores humanas involucradas en el 
proceso metastásico y su caracterización funcional y transcriptómica al nivel individual. El trasplante 
In vivo de las células tumorales circulantes (CTC) mostró que poseen alto potencial tumorigénico y 
metastásico. Secuenciación individualizada del RNA reveló que las CTC se agrupan  por separado de 
su correspondientes células tumorales primarias y metastásicas, mostrando baja expresión  de genes 
asociados con el ciclo celular y el matriz extracelular y  enriquecimiento de genes implicados en la 
biogénesis de ribosomas. Además, los CTC mostraron una expresión elevada de numerosos genes 
relacionados con el cáncer incluyendo Survivina, AurkA, y AurkB, entre otros. Por otra parte, la 
expresión de la proteína Survivina se detectó en  los tumores primarios y las lesiones metastásicas de 
todos los modelos metastásicos. El tratamiento preclinico con YM155 (supresor de Survivina) 
disminuyó la carga tumoral metastásica y mostró efectos beneficiosos sobre la supervivencia de los 
ratones portadores de los tumores ortotópicos. Además, la resección del tumor primario en 
combinación con YM155 resultó en una mejora significativa en la supervivencia media de los 
ratones en comparación con el grupo control. Finalmente, la caracterización proteómica de los 
exosomas de cáncer pancreático aislados de los  tumores primarios y los organos metastásicos de los 
modelos PDX reveló firmas proteómicas órgano-específicas con abundante expresión de proteínas 
humanas algunas de ellas reportadas de tener papel en el organotropismo metastatico. 
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I. INTRODUCTION. 
1.1.Pancreatic ductal adenocarcinoma. 
1.1.1. Anatomy of pancreas and pancreatic cancer types. 
The pancreas is a retroperitoneal organ located behind the stomach in the upper left abdomen. As 
illustrated in Figure 1, the pancreas is anatomically divided in head, neck, body and tail parts. The 
head is the widest and thickest part lying within the curve of the duodenum and over the inferior 
vena cava. The head is composed of an additional lobe called ucinate process, which is grooved by 
the superior mesenteric artery and the superior mesenteric vein. The neck connects the head to the 
body of the pancreas, it is grooved by the posterior mesenteric vessels, and it lies in front of the 
commencement of the portal vein. The body is the middle and longest part of the pancreas, that is 
located between the neck and the tail, where the mesenteric artery and vein pass behind this part of 
the pancreas. The tail is the narrowest part of the gland, located in the left side of the abdomen and 
its end contacts the splenic hilium. The pancreas is both an exocrine and an endocrine gland. The 
exocrine part is composed of acini cells, which secrete various digestive enzymes and 
bicarbonates. The endocrine pancreas is made up of the islets cells(called the islets of Langerhans), 
which are isolated clumps of endodermal cells divided into four cell types: alpha cells (produce 
glucagon), beta cells (produce insulin), delta cells (produce somatostatin) and PP cells (produce 
pancreatic polypeptides) [Figure1]. 
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Figure 1. Anatomy of pancreas. (A). Gross anatomy of the pancreas indicating its close 
anatomical relationship with the duodenum and common bile duct. (B). The major components of 
the pancreatic parenchyma on a celular level. (Figure adapted from Encyclopaedia Britannica, Inc., 
© 2003.) 
 
Pancreatic cancer is the third leading cause of cancer death in developed countries with a 5-year 
survival rate of only 5% [1,2]. There are several histological types of malignant tumors in the 
pancreas, with pancreatic ductal adenocarcinoma (PDAC) variant represents the most common 
type (80-90%). The other less frequent pancreatic exocrine and endocrine neoplasms are shown in 
Table 1. 
                   Table 1. Histological classification of pancreatic neoplasms [3-5]. 
Histological type  Origin  Frequency  
PDAC  Exocrine    80-90%  
Acinar cell carcinoma  Exorcine    2%  
Mucinous cystadenocarcinoma  Exocrine    3%  
Serous cystadenocarcinoma  Exocrine    <1%  
Intraductal papillary mucinous neoplasm  Exocrine    1-3%  
Pseudopapillary carcinoma  Exocrine    <1%  
Pancreatoblastoma  Exocrine    Rare  
Gastrinoma  Endocrine    1-2%  
Insulinoma  Endocrine    1-2%  
Glucagonoma  Endocrine    <1%  
Somatostatinoma  Endocrine    Rare  
Vipoma  Endocrine    <1%  
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1.1.2. Staging classification of exocrine pancreatic cancer. 
The most widely used staging system for exocrine pancreatic cancer was defined by the American 
Joint Committee on Cancer in agreement with the TMN Committee of the International Union 
Against Cancer [6]. This classification determines the anatomical extent of the disease, including 
the size and invasiveness of the primary tumor (T), the presence of regional nodal metastases (N), 
and the existence of distant metastasis (M). For pancreatic cancer, in particular, local extension of 
the primary tumor may result in unresectability. This is reflected in the staging system, where T3 
primary tumors extends beyond the pancreas without involvement of unresectable structures, but 
T4 primary tumors involve structures such as celiac axis or superior mesenteric artery and they are 
classified as unresectable tumors. Table S1 illustrates the components of this staging system, 
including the anatomic stage of the disease and the prognostic groups.  
1.1.3. Preneoplastic pancreatic lesions and their genetic features. 
It has been shown that PDAC develops through a stepwise progression from preinvasive lesions, 
including intraductual papillary mucinous neoplasia (IPMNs), mucinous cystic neoplasia (MCNs), 
and pancreatic intraepithelial neoplasia (PanINs) to invasive neoplasms [7]. The IPMNs are 
mucin-producing epithelial neoplasms, which grow in the main duct (MD-IPMN) or branch duct 
(BD-IPMN) of the pancreas and are characterized by papillary architecture, intraductal 
proliferation of neoplastic duct epithelium, accompanied by mucin production. Based on their 
histological features, the IPMNs are subdivided in gastric, oncocytic, pancreatobiliary, and 
intestinal subtypes. On the other hand, the MCN precursor lesions mainly arise in women and are 
usually located in the pancreatic body and tail. In contrast to IPMNs, MCNs do not connect with 
the main pancreatic duct. Histologically, the MCNs are composed of mucinous epithelial lining, 
which consists of columnar cells with a varying degree of dysplasia and it is associated with an 
underlying ovarian-like stroma. 
 
The third and best-characterized precursor lesion in the pancreas are the PanINs. Based on the 
degree of epithelial atypia, the PanINs are subdivided in four different grades: PanIN-1A, PanIN-
1B, PanIN-2, and PanIN-3 [8]. PanIN-1 is a common incidental lesion, characterized by only 
minimal atypia and it may be found in up to 40% of noncancerous pancreata. Moreover, PanIN-1 
lesions are divided into flat (PanIN-1A) and papillary (PanIN-1B) types. The lesions with 
moderate atypia are designated PanIN-2, whereas those with pronounced atypia are PanIN-3, 
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which is more closely associated with invasive carcinoma, and are detected in 30-50% of 
pancreata with infiltrating ductal carcinoma. Normally, it is difficult to follow the progression of 
PanINs to invasive carcinoma, because PanINs are radiographically undetectable and they are 
usually only seen in pancreatectomy specimens. However, a few clinical cases of progression have 
been reported [9-11], which further support the precursor nature of PanINs. 
 
Most of the genetic alteration of infiltrating ductal carcinoma is identified at different stages in the 
PanINs progression. These alterations include telomere shortening and somatic mutations in the 
KRAS oncogene, CDKN2A (p16), TP53 and SMAD4 tumour suppressor genes [12]. One of the 
earliest events in pancreatic tumorigenesis is a telomere shortening responsible for inducing 
genetic instability and activation of KRAS oncogene, mainly through single point mutations in 
codon 12. The tumor suppressor gene p16 is frequently found inactivated in early stages of PanIN 
progression. Mutations in two additional tumor suppressor genes, TP53 and SMAD4, are often 
associated with progression of PanIN-3 lesions to invasive ductal carcinoma. Figure 2 illustrates 
the progression model of pancreatic carcinoma and the mutation frequency of the genes in each of 
the PanINs lesions. 
        
Figure 2. Progression model of pancreatic carcinogenesis. The top figure shows the 
morphologic progression model of pancreatic carcinogenesis. Illustrated from left to right are 
histological examples of a normal pancreatic duct, the PanINs classified in four groups, and 
infiltrating carcinoma, respectively. The bottom figure illustrates the genetic progression model of 
pancreatic cancer. The genetic alterations arising during pancreatic carcinogenesis are classified 
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into four events: early event - telomere shortening and constitutive activation of KRAS oncogene, 
intermediate event - inactivation of CDKN2A tumor suppressor gene and late event – inactivation 
of TP53 and SMAD4 events. The figures are taken from Feldmann Get et al.(2007) and 
Macgregor-Das et al. (2013). [12-13].  
 
1.1.4. Molecular Genetics of Pancreatic cancer. 
A great effort has been made in the past years to study the molecular mechanisms of this 
genetically complex disease. Numerous genetic alterations have been identified in pancreatic 
cancer, including amplifications and homozygous deletions, copy-number gains, chromosomal 
rearrangements and loss of heterozygosity (LOH) with and without copy number changes [10-13]. 
However, the spectrum of the altered genes and the types of alterations makes each pancreatic 
tumor distinctive. 
The most frequent mutations in the PDAC are those described previously in the progression 
model, including the KRAS oncogene (99%) and tumor suppressor genes: CDKN2A/ p16 (90%), 
TP53 (85%) and SMAD4 / DPC4 (55%). K-ras (12p12.1) encodes a membrane-bound GTP- 
binding protein, which triggers various cellular functions, such as the transition through the G1 
phase of the cell division cycle, survival, motility, and cytoskeletal remodeling. The K-ras 
activating mutations abrogate the GTP-binding pocket of the K-ras protein, which in turns 
converts the protein constitutively active. Somatic mutations of the codons Gly12, Gly13, or 
Gln61 are normally associated with permanently active K-ras. [18-19]. 
The second most frequent genetic alteration in pancreatic cancer occurs in CDKN2A (p16,9p21.3) 
gene, which is one of the most frequently mutated genes in cancer. P16 is considered as tumor 
suppressor gene, which regulates cell cycle progression by blocking the Rb phosphorylation 
through inhibition of cyclinD-CDK4/6 complex, whose function is mediating the commencement 
of the G1/S phase transition. The inactivation of p16 can occur through multiple mechanisms such 
as homozygous deletion, promoter hypermethylation or intragenic mutations [20-21]. Inactivation 
of p16 alone or in combination with activity of other oncogenes make a significant contribution to 
the formation of the pancreatic precursor lesions and their progression to pancreatic cancer.  
TP53 (p53,1713.1) is another frequently mutated gene in pancreatic cancer. TP53 is tumor-
suppressive gene, which main function is maintenance of a G2/M arrest and regulation of a G1/S 
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transition to facilitate normal cell cycle progression. Inactivating mutations in TP53 gene occur in 
more than 50% of sporadic pancreatic cancers, and they normally abolish the ability of the protein 
to bind to DNA and activate gene transcription [22-23]. In contrast to other tumor suppressor 
genes, homozygous deletions of TP53 are rarely identified; most of the alterations are missense 
mutations.  
 SMAD4 (18q21.1) is a tumor suppressor gene, that is commonly inactivated in approximately 
45% of pancreatic cancers, mainly through homozygous deletion mutations [24-27]. SMAD4 is a 
member of TGFβ signaling and it has been shown to negatively regulates the tumor initiation and 
progression [28-29]. Functional characterization has demonstrated that the loss of SMAD4 
promotes the TGFβ-mediated cancer cell growth and metastasis.  
               
1.1.5. Treatment of PDAC. 
Currently the most effective treatment is surgery, mainly due to the low success rate of most drug 
therapies. In this sense, various strategies are being investigated, based on the use of chemotherapy 
with or without radiotherapy, administered in the adjuvant or neoadjuvant settings. The current 
postsurgical treatments for PDAC are 5-fluorouracil, gemcitabine and nab-paclitaxel. Patient with 
metastatic pancreatic cancer are candidates for combination therapy with gemcitabine plus 
erlotinib, gemcitabine plus nab-paclitaxel, or the multidrug regimen of FOLFIRINOX (leucovorin, 
fluorouracil, irinotecan, and oxaliplatin) [30]. 
The median survival of patients treated with surgery is about two years, however this time 
decreases dramatically to 6-8 months in patients diagnosed with metastatic disease [31,32]. 
Therefore, alternative therapeutic strategies are urgently needed in PDAC. 
 
1.2. Cancer metastasis. 
 The ability to develop metastasis is considered the most life-threatening feature of neoplastic cells 
and it is the first cause of cancer‐related morbidity and mortality [33]. The metastases represent a 
subset of cells that escaped from primary tumor and colonized distant organs. This subset of 
metastatic cells is phenotypically distinct from the primary tumor cells, and the molecular 
mechanisms underlying these phenotypic characteristics of metastatic cells are currently being 
investigated.  
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1.2.1. Routes of dissemination. 
Tumor dissemination may follow several routes, including local invasion, lymphatics or 
hematogenous spread, or direct seeding of body cavities. Another less common routes of spread 
have also been described, including dissemination of cancer cells trough the space between 
endothelium and basement membrane or perineural invasion in pancreatic and prostatic 
carcinomas. In this doctoral thesis, the hematogenous dissemination is the principal focus of 
study. 
 
1.2.2. Metastasis progression models. 
There are two distinct models which to some extend explain the phylogeny and progression of 
metastatic disease. These models are linear progression and parallel progression model and are 
discussed in the following chapter. 
 
Linear progression model. 
This model proposes that cancer cells can undergo multiple selective rounds of mutations within 
the primary tumor, and only a small subgroup of these tumor cell clones will acquire the genetic 
and epigenetic alterations necessary for generation of metastasis-competent cell clones (illustrated 
in Figure 3) [34]. The model also suggests that larger tumors may contain more metastasis-
competent cells within the whole heterogeneous tumor population. Therefore, this fits well with 
TNM international classification system claiming that tumor size is associated with higher 
metastatic frequency. According to the model conception, metastasis founder cells usually spread 
at late stages of disease, and this is supported by evidences in the literature showing that the most 
invasive primary tumors exhibit a close genetic similitude with their corresponding metastases 
[35]. These metastatic cells can also disseminate from a first metastatic site to other organs, thus 
resulting in sequential development of multiple metastastatic lesions [36]. 
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Figure 3. The linear progression model. Cancer cells within primary tumor cells continuously 
acquire numerous genetic alterations by which some of these cells can transform into metastasis-
competent clones. At the late stage of primary tumor progression, metastatic clones within the 
primary tumors start to disseminate and subsequently develop into micro and overt 
macrometastases. Tumor cells from the first metastatic site may also colonize other organs, thus 
generating multiple and successive metastatic lesions. The Figure is taken from Klein, (2009) [39]. 
 
Several recent studies have shed new light on the genomic evolution during tumor progression. 
For example, Aparicio and collegues sequenced a breast cancer metastasis and its matched primary 
tumor, resected 9 years earlier and found that 11 out of 30 mutations that were identified in the 
metastatic lesions were also present in the primary tumor [37]. Therefore, this study demonstrated 
that some of the mutations in the primary tumor are also selected in the metastasis, but the 
genomic evolution occurring during metastatic progression is also prominent. In another study, 
Yachida and colleagues performed genomic sequencing studies to investigate the phylogenetic 
relationship between pancreatic primary tumors and their corresponding metastasis [38]. The 
authors suggest that metastasis is a late event in the genetic evolution of pancreatic cancer, 
showing that clonal populations which give rise to metastasis are also present within the primary 
tumor, but they are more genetically evolved than parental non-metastatic clone. Moreover, using 
mathematical modeling, they concluded that the appearance of metastasis-competent clones within 
the primary tumor takes place 10 years after tumor initiation and they spread 5 to 6 years later 
from the primary tumor.  
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In another in-depth study, Makohon-Moore and colleagues performed whole-genome sequencing 
of 39 samples including 26 metastatic lesions, up to 3 distinct regions of each primary tumor, and 
corresponding normal tissues obtained from untreated patients who died of metastatic pancreatic 
cancer [39]. They identified 614 somatic mutations, which they used to assess the genetic 
heterogeneity between primary tumors and metastases.  The results showed that each patient 
harbored unique set of driver mutations that were present in both primary and metastatic tumors. 
Therefore, these findings indicate little variability of driver mutations in these PDAC patients and 
specific driver mutations of metastasis were not identified in this study.  
McDonald and colleagues recently published a paper, where they used a large panel of matched 
primary and metastatic PDAC samples obtained from five untreated patients to study the impact of 
epigenetic heterogeneity on the pancreatic cancer progression [40]. Interestingly, the authors 
revealed massive epigenetic changes with chromatin modifications including global 
reprogramming of histone H3K9, DNA methylation within large heterochromatin domains 
(LOCKs) and gene regulatory modifications, both in the distant ( liver lung) metastasis and in the 
primary tumor subclones they came from. They also discovered that distant metastases and their 
precursors processed glucose through the oxidative pentose phosphate pathway. Moreover analysis 
of all glycolytic and pentose phosphate metabolites identified a depletion of 6-phosphogluconic 
acid (6PG), which is the substrate for 6-phosphogluconate dehydrogenase (PGD) enzyme. To test 
whether PGD and the pentose phosphate pathway were tightly linked to the epigenetic changes, 
the researchers treated the tumor cells from different sites with 6-aminonicotinamide (6AN), which 
is a drug known to inhibit PGD but is not used in humans because of its severe side effects. They 
reported that this drug had no effect on the epigenetic state of DNA from the regional metastasis, 
but it reversed the epigenetic changes observed in cells from the distant metastasis, as well as 
reduced tumorigenicity in tumour forming assays, whereas normal and peritoneal metastatic cell 
were not affected by this treatment. Therefore, these two studies nicely demonstrated that there is 
little heterogeneity in driver mutations between primary and metastatic PDAC tumors, but there is 
considerable epigenetic reprogramming. 
 
Parallel progression model. 
In contrast to linear model, the parallel progression model proposes that primary tumor and 
metastatic lesions undergo an independent and parallel acquisition of genetic and epigenetic 
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alterations (illustrated in Figure 4) [41]. According to this model, the seeding of metastatic 
competent cells occurs very early, long before the primary tumor is clinically detectable. For 
example, Christoph Klein and colleagues observed that the genetic alterations in the DTCs in the 
bone marrow of patients with breast cancer are distinct from those in their corresponding primary 
tumors [42]. These data suggest that the genetic and epigenetic evolution may happen through 
multiple rounds of genetic diverseness and clonal selection mostly within the distant organ sites in 
which overt metastasis ultimately develop. Therefore, the parallel progression model suggests high 
genetic divergence between primary tumor and metastasis-competent cells, that may somehow 
explain their different response to systemically administered drugs, reported in several cancer 
types [43]. 
                             
 
                                  
Figure 4. The parallel progression model.  
The Figure shows the Metastasis Initiating Cells (MICs), which are spreading early from the 
primary tumor mass. According to this model, these metastatic cells evolve independently from 
primary tumor cells and acquire genetic alterations, that are specific for their target organ 
microenvironment. Before developing into overt macrometastasis, some of these metastatic cells 
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may enter into dormancy state in case of long metastatic latency. The Figure is adapted from 
Klein, (2009) [41].  
1.2.3. The Metastatic cascade. 
Metastasis is a complex process involving a series of steps by which a subset of metastatic tumor 
cells escape from the primary tumor site and disseminate to distant organs, where they form new 
lesions [44,45]. Some tumors are highly metastatic, capable of forming secondary lesions with 
high frequency (small-cell carcinoma of the lung, melanoma, pancreatic carcinoma), whereas 
others tumor types rarely metastasize to other organs, despite being locally invasive (basal cell 
carcinomas of the skin, glioblastoma multiforme). If a tumor cell with invasive properties cannot 
complete any step in the metastatic cascade, it cannot form a metastasis. Therefore, each tumor 
cell must complete every step of the metastatic cascade. 
The metastatic cascade include the following steps: 
 
A)  Tumor Invasion. 
Tumor invasion is the first step in the cancer dissemination, defined as the capacity of tumor cells 
to break the basement membrane and invade the surrounding stroma. This process requires 
important morphological and phenotypic changes, including adhesion, extracellular matrix (ECM) 
reorganization, and motility. An important biologic process, known as epithelial-mesenchymal 
transition (EMT) required for normal embryonic process, has also been implicated in tumor 
invasion. The EMT is characterized by transformation of a tumor cell with an epithelial-like 
morphology to a nonpolarized, motile and spindle-shaped tumor cell with a fibroblast-like 
morphology [46]. Normally, EMT is associated with downregulation of epithelial-specific E-
cadherin and keratins and upregulations of mesenchymal markers including intermediate-filament 
vimentin, α-SMA, FSP1, and desmin among others. A key regulators of EMT are the zing finger 
transcriptional repressors Snail and Slug, which have been implicated in regulating EMT by their 
ability to repress E-cadherin transcription. Additional transcriptional factors such as TWIST, 
FOXC2, ZEB1, ZEB2 [47], non‐codingRNAs including the miR200 family (miR200a, miR200b, 
miR200c, miR141 and miR429), and the miR205 family [48] have been also reported to play a 
role in inducing the EMT program. In the absence of these EMT-inducing factors, tumor cells may 
also reverse the EMT process by undergoing a mesenchymal-epithelial transition (MET). 
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The ECM provides structural and biochemical support to the surrounding cells and regulates the 
cellular behaviour. The ECM can be remodelled by various enzymes, secreted by the tumor cells 
and surrounding stromal cells [49], which contributes to matrix degradation and tumor cell 
invasion. Proteolytic enzymes of many classes have been involved in tumor invasion, such as the 
serine proteinases, plasmin, plasminogen activator and matrix metalloproteinases (MMPs) among 
others. For example, it has been shown that upregulation of MMPs correlates with invasion, 
metastasis and poor prognosis in many cancer types. In addition, studies with animal models 
provide evidence for the importance of MMPs in cancer progression [50]. This scientific evidence 
describing the role of MMPs in tumor progression resulted in development and testing of synthetic 
MMPs inhibitors for cancer therapy [51]. However, these inhibitors did not show efficacy in 
clinical trials, probably due to issues with the inhibitor molecule or clinical trial design and a lack 
of knowledge about the broad spectrum of MMP activities. 
 
B)  Intravasation.  
 Intravasation of tumor cells is an active process that requires the distruption of endothelial 
junctions for the cancer cells to cross the endothelium of the blood vessels, a process known as 
transendothelial migration (TEM). Tumor blood vessels are highly abnormal, with weak 
endothelial junctions through which cancer cells can easily enter the bloodstream [52]. Various 
proteins have been described to play a role in intravasation. For example, COX2, EPIREGULIN, 
MMP1, and MMP2 participate in mediating breast cancer cell intravasation in the pulmonary 
parenchyma [53]. On the other hand, it has been recently described that the cytokine 
ANGIOPOIETIN LIKE 4 (ANGPTL4) is also able to trigger the infiltration of tumor cells into the 
lungs by inducing the dissociation of endothelial cell‐cell junctions [54].  
 
C) Transport through blood circulation. 
The transport of tumor cells through circulatory system can be an active process governed by 
motility mechanisms or a passive process, where the tumor cells may be passively carried or 
pushed along with the blood flow. In blood circulation, many tumor cells are eradicated by the 
immune cells such as NK cells before seeding the secondary organs. Also, the tumor cells which 
were able to evade the immune system are often eliminated by exposure to shear forces generated 
by flowing blood [55]. In addition, the resistance and behavior of the tumor cells during transport 
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process often depend on whether they are present as single cells or as emboli. Generally, the 
embolization is divided in two types: homotypic (tumor cell-tumor cell) or heterotypic (tumor cell-
leukocyte/platelet). The tumor cells present as emboli are usually more resistant to shear forces or 
immune attacks.  
During the transport process, the tumor cells in blood circulation, known as circulating tumor cells 
(CTCs) are weakly adherent and subject to anoikis, which is a type of apoptosis, where the 
anchorage-dependent tumor cells are triggered to undergo programmed cell death [56]. In general, 
metastasis-competent cells are thought to be more resistant to anoikis than non-metastatic tumor 
cells.  
 
D) Arrest  
The physical entrapment within the small capillaries of distal organs and the arrest of CTCs in the 
microvasculature, as well as selective adhesion to the endothelium wall are two different 
processes. Both processes have been widely reported and the importance of these mechanisms in 
specific organs remains under debate. For instance, the specific adhesion of CTCs to microvessel 
endothelial cells at the future metastatic organs is considered to be one of the most important steps 
of the metastatic process, and this step is termed as organ-specific metastasis. Normally, the 
metastatic cancer cells, which exert higher rates of selective adhesion to microvessel endothelial 
cells result in higher metastatic incidence. In this regard, many In vivo and In vitro kinetic studies 
have demonstrated that the initial adhesion of CTCs takes place preferentially at endothelial cell 
junctions [57]. Moreover, it has been shown that the tumor cells frequently adhere at sites of 
inflammation and this is normally accompanied with modifications in cell surface components of 
endothelial cells at the sites of inflammation. Many tumor cells may also use common mechanisms 
to adhere to and pass through endothelium as the inflammatory cells. 
 
G) Extravasation  
During extravasation the tumor cells move from the interior of the vessels into parenchyma of the 
target organ. In general, the molecular mechanisms governing the extravasation process are similar 
to those involved in invasion, including proteinases, motility factors and cellular adhesion 
molecules. For example, various genes have been implicated in the process of extravasation of 
breast-cancer CTCs into the lungs of preclinical models and it has been found that these genes are 
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also associated with lung metastasis in the clinic. Some of these genes are Fascin-1 and other 
members involved in invadopodia, epiregulin; WNT ligands which mediate cancer-cell motility 
[58,59], and ANGPTL4, VEGF, COX2, MMP1, osteonectin which are mediators of endothelial 
disjunction and vascular permeability [60-63]. It has also been reported that platelets can form 
clusters with CTCs and induce extravasation through secretion of TGF-β [64], or altering the 
endothelial cell-to-cell junctions by releasing adenine nucleotides [65]. The interaction between 
macrophages and CTCs also facilitates the migration of CTCs from capillary walls into the lung 
parenchyma [66].   
 
F) Colonization  
During colonization step, the tumor cells start to form clusters at secondary organ sites and this 
process is considered one of the most complex and rate-limiting in metastatic cascade. The tumor 
cells which survive upon infiltration of distant organs, known as disseminated tumour cells 
(DTCs), can reside in the bone marrow of cancer patients for long periods, however only a few of 
these patients develop overt metastasis [67]. In some tumor types such as melanoma and breast 
cancers, metastases can become clinically detectable decades after the resection of the primary 
tumor, indicating that the tumor cells can remain in a state of dormancy for long time. The 
capacity of DTCs to switch from dormancy to active proliferation may depend on cell-non-
autonomous mechanisms, needed to convert the surrounding microenvironment into more 
favourable niche. For example, it has been proposed that the outgrowth of DTCs might also 
depend on the activation and mobilization of bone marrow-derived cells (BMDCs) and their 
subsequent recruitment to the metastatic organs. These processes may be triggered by systemic 
factors secreted by cancer cells, including osteopontin (OPN) or SDF-1 [68-69]. On the other 
hand, it has been hypothesized that the cancer cells in occult micrometastases may proliferate 
continuously without dramatic increase in their overall number, which is probably due to a high 
apoptotic rate. One possible explanation for this phenomenon could be the failure of the DTCs to 
induce neoangiogenesis [70]. For example, it has been reported that prosaposin (Psap) may inhibit 
metastatic colonization by promoting expression of the anti-angiogenic factors such as 
thrombospondin-1 in stromal cells [71]. On other hand, Angiopoietin 2 (Angpt2) has opposite 
effect and it is able to stimulate the metastatic colonization of breast and pancreatic carcinomas by 
promoting the capacity of infiltrating myeloid cells to support the vascularization of metastatic 
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lesions [72]. Figure 5 illustrates a scheme of the metastatic cascade, including all steps discussed 
in this chapter. 
                          
Figure 5. Scheme of the metastatic cascade. Metastasis initiating cells (MICs) disseminate either 
through blood circulation or through lymphatic system. In both scenarios, MICs detach from the 
primary tumor and migrate through the basement membrane. In the case of a haematogenous 
spread, MICs have to intravasate into circulatory system, survive in the blood circulation and 
extravasate from the vasculature endothelium to colonize the distant sites. The figure is adapted 
from Pantel and Brakenhoff, (2004) [73].  
 
1.2.4. Metastasis organotropism. 
Metastatic organotropism is the tendency of the cancer cells to establish metastatic tumors in 
specific organ sites. The patterns of metastatic distribution may depend on anatomic or mechanical 
characteristics. For example, the first capillary bed where CTCs become arrested is determined by 
patterns of blood circulatory system in the body [74]. The venous circulation usually leads to the 
right ventricle of the heart and to the lungs, except the venous system from the gut, which drains 
the blood first into the liver. For this reason, it is usually reported high metastatic incidence in liver  
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and lung organs [75]. In 1889, Stephen Paget spread the concept that the pattern of metastatic 
organ distribution is not accidental and metastatic cells establish overt metastasis only when the 
“seed” (tumor cells with metastatic capability) and the “soil” (organs or tissues providing 
favorable growth factors to seeds) are compatible, thus suggesting that the dissemination of 
metastatic cells is organ specific and not merely anatomic [76]. The mechanisms responsible for 
organ selectivity can be attributed to the capability of the tumor cells to recognize subendothelial 
basement membrane differences. For example several In vitro studies demonstrate organ-selective 
adhesion, invasion and growth [77-78]. There is a notion that metastatic tumor cells arrive in a 
premetastatic niche that was previously initiated in target organs by tumor-secreted systemic 
factors. It has been reported that BMDCs that express VEGFR1 and several integrins, selectively 
adhere to the future metastatic sites, where secretes different proteinases and chemokine factors 
and thus prepare a permissive niche for colonization by upcoming tumor cells [79]. 
Recently, it has been shown that tumor-derived exosomes, a small membrane-bound extracellular 
vesicles (size 30-100nm) carrying functional biomolecules (DNA, RNA and proteins) are able to 
determine organotropic metastasis. A recent study demonstrates that tumor-secreted exosomal 
integrins can determine organ-specific metastasis by fusing with host-specific resident cells to 
establish supportive metastatic environments through activation of Src phosphorylation and pro-
inflammatory S100 expression [80]. In this study, it has been found that the exosomes expressing 
ITGa6β4 and ITGa6β1 integrins co-localized with S100A4-positive fibroblast cells and resident 
epithelial cells expressing pulmonary surfactant protein C in laminin-rich lung microenvironments, 
while the ITGavβ5-positive exosomes expressed by pancreatic cancer cells have been found to co-
localize with F4/80
+
 macrophages and to fuse with resident Kupffer cells in fibronectin-rich liver 
niches. The authors also demonstrated that inhibition of these exosomal specific integrins by short 
hairpin RNAs significantly reduced the exosome uptake and markedly decreased metastatic tumor 
burden in lung and liver mouse organs. In addition, the clinical data identified that the levels of 
ITGa6β4 are higher in exosomes isolated from circulating plasma of breast cancer patients with 
lung metastasis, as well as increased levels of exosomal ITGavβ5 were detected in pancreatic 
cancer patients diagnosed with liver metastasis in comparison to those without metastasis. Figure 6 
summarizes the mechanisms responsible for metastasis organotropism. 
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Figure 6. Metastasis organotropism triggered by tumor-derived systemic signals. Tumor-
secreted systemic signals such as tumour-derived inflammatory cytokines, exosomes and 
extracellular-matrix-remodelling enzymes recruit bone-marrow-derived cells and precondition the 
microenvironment of distant organ for upcoming tumor cells. Different types of proteins and lipids 
transported by the tumor-derived exosomes can also fuse with resident cells of the future 
metastatic site and establish the pre-metastatic niche. The figure is adapted from Liu Y, Cao X. 
(2016) [81].  
 
1.3. Experimental metastasis models. 
Animal models are frequently utilized as a useful tool to recapitulate the entire metastatic cascade. 
The most commonly used strategy to model cancer metastasis is based on injecting mouse or 
human tumor cells directly into mouse circulation via the tail vein or left ventricle of the heart 
[82,83]. This model bypasses important steps such as invasion and intravasation, and therefore 
cannot recapitulate the whole multi-step metastatic process. Over the past decades, many 
Genetically Engineered Mouse Models (GEMM) models have been generated through 
incorporation of cancer-associated genetic mutations. These models accurately perpetuate the 
genetics and phenotype of several tumor types including pancreatic cancer. However, despite their 
multiple advantages, the GEMM models generally exhibit long tumor and metastatic latency or 
low metastatic incidence [84], thus making them less attractive model for studying metastatic 
disease.  
Spas Dimitrov Markov 
18 
 
 
Patient-derived xenografts (PDX) have become other popular models for studying cancer disease 
[85]. The PDX models generated by subcutaneous engraftment of patient tumors in nude mice, 
usually provide extensive local growth of primary tumor, but rarely metastasize to distant organs 
[86-87]. In contrast to subcutaneous transplants, the orthotopic transplantation is more frequently 
associated with distant metastasis [88] and multiple overt macrometastasis can be easily achieved, 
especially if the primary tumor graft is surgically removed [89]. The surgical resection of primary 
tumor can prolong survival and give sufficient time for metastatic cells to colonize the distant 
organs and form metastatic lesions, thus recapitulating the multiple sequential steps of the 
metastatic cascade. Nevertheless, the primary tumor removal is not an indispensible requirement 
for establishment of metastatic models of pancreatic cancer. For example, several studies reported 
successful metastatic spread of pancreatic xenograft tumors transplanted orthotopically in nude 
mouse model [90-91]. However, the metastatic rate in these models still remains unsatisfactory 
low, which is consistent with previous findings in breast xenograft models demonstrating that the 
immune status of the host mice strain can have a huge impact on establishment of distant 
metastasis [92]. Table 2 summarizes the preclinical models of spontaneous human metastasis 
described in the literature.  
 
      Table 2. Examples of preclinical models of spontaneous human metastasis. 
                 Model  
Common sites  
of metastasis  
reference  
Breast(213/LM2-4)  Lung        [89]  
Breast(H2N/met2)  Lung and lymph nodes        [93]  
Colon(KM12)  Lymph nodes and liver        [94]  
Colon(Co-3,Col-3-JKC and Col-5-
JCK)  
Liver        [95]  
Colon(LSLiM6)  Lymph nodes and liver        [96]  
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Gastric(St-4, St-40, H-111 and Sc-
1HU)  
Lymph nodes and liver        [95]  
Melanoma (113/6-4L)  Lung        [97]  
Melanoma(113/4-5B1 and 113/4-
5B2)  
Lung and central nervous  
system  
      [97]  
Pancreatic(Panc-4)  Liver and peritoneum        [90]  
Ovarian(RMG-1)  
Peritoneum, lymph nodes 
and diaphragm  
      [98]  
      Table 2 is adapted from Francia G et al. (2011) [82].  
 
1.4. Single-cell Sequencing technology. 
The classical method in studying gene expression is to analyze the messenger RNA (mRNA) 
content of large pools of cells. However, tissue is composed of heterogeneous populations of cells 
where much variation takes place at the single-cell level. For example, tumor tissue is 
characterized by heterogeneous populations of multiple clonal expansions [99-101]. Therefore, 
analyzing a tumor tissue as a whole could mask important characteristics of the disease. Recently, 
various research groups have developed molecular techniques to overcome the challenges of 
sequencing small amounts of mRNA inside a single-cell. 
 Single-cell RNA-Seq became a powerful tool for studying the gene regulatory network at the 
single-cell level. This approach has been applied to single-cell studies including human 
preimplantation embryos, human embryonic stem cells, single-cells from dissected hippocampal 
tissue of mouse, and immune cells from mouse [102-103]. Commercial microfluidic approaches 
such as the Fluidigm C1 system have also been developed for analyzing up to 96 single-cell RNA 
profiles in parallel using nanoliter reaction volumes. In addition, this system allows the single-cell 
cDNA synthesis to take place in individual microfluidic chambers and show advantages over tube-
based approaches, including improved mRNA capture efficiency and detection sensitivity. 
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1.4.1. Intratumoral heterogeneity during metastastic progression. 
Several models of metastasis have been hypothesized, including late dissemination, early seeding, 
and self-seeding, but yet little is known about the molecular mechanisms driving the metastatic 
progression and dissemination of the primary tumor cells into distant organs. The major challenges 
in better understanding the metastatic disease are resolving the intratumoral heterogeneity and 
deciphering the genomic information of circulating tumor cells (CTCs), considered as the 
precursors of metastasis. The problem is that CTCs are presented at very low number in the blood, 
and generally only 1–50 cells can be enriched from 7.5-mL peripheral blood, which provides 
limited input material for genomic studies.  
Several studies have attempted to decipher the transcriptional heterogeneity of CTCs at single-cell 
resolution. For example, in melanoma patients, scRNA-seq revealed three distinct gene signatures 
in CTCs, that are associated with metastasis [104]. In another study, scRNA-seq identified 
plakoglobin as a key regulator of CTC clusters in metastatic breast cancer patients and mouse 
xenograft models [105]. Using a orthotopic xenograft models, this study showed that CTC clusters 
exhibit increased metastatic potential compared to individual CTCs and inhibition of plakoglobin 
by short hairpin RNAs (shRNAs) markedly reduced the number of CTCs in the blood circulation, 
as well as the number of lung metastatic nodules. In another study, scRNA-seq was applied to 
study metastasis in GEMM models of pancreatic cancer and showed that the CTCs clustered 
separately from their primary tumors, showing low-proliferative signatures and are enriched for 
extracellular matrix genes [106]. In this study, the scRNA-seq data identified that SPARC was 
overexpressed in pancreatic CTCs and its knockdown by shRNAs resulted in suppression of cell 
migration and invasiveness in In-vitro wound scratch assay, as well as reduction of lung metastasis 
in orthotopic xenograft models. Therefore, this data demonstrate that CTCs of pancreatic cancer 
may have a very high level of heterogeneity, which is presumably related to their capacity of 
establishing distant metastases. However, since GEM KPC mice only produce disseminated 
micrometastatic foci, the authors were unable to directly compare the expression profile of CTCs 
with that of metastatic lesions and therefore the question whether pancreatic cancer metastasis is 
hierarchically organized phenomenon still remains unanswered. 
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II. OBJECTIVES. 
The principal objective of this thesis is the development of metastatic PDX models of pancreatic 
cancer, which can serve as an efficient and reproducible In-vivo platform for modelling the whole 
multi-step metastatic process, which in turns can facilitate the discovery of novel molecular 
mechanisms involved in cancer dissemination, as well as development of more effective 
therapeutic strategies for metastatic pancreatic cancer. For this reason, we defined the following 
objectives: 
 
1. Establishment of metastatic patient-derived tumor xenograft (PDX) model of pancreatic 
cancer to faithfully recapitulate the multi-step metastatic process. 
 
2. Identification, purification and enrichment of the human tumor populations from primary 
tumor, blood and metastatic sites of metastatic PDX models. 
 
3. Single-Cell RNA Sequencing of the human tumor populations enriched from the primary 
tumor, mouse blood and metastatic sites of PDX model with aim to: 
 
       -  decipher the transcriptional heterogeneity during metastatic disease. 
       -  identify potential anti-metastatic targets. 
 
4. Pre-clinical evaluation of anti-metastatic effect of therapeutic agents that block the activity 
of the previously identified deregulated genes or pathways implicated in metastatic process. 
 
5. Studying the role of tumor-derived exosomes in organotropic metastasis.    
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II. MATERIAL AND METHODS  
3.1. Establishment of metastatic Patient-derived xenograft (PDX) models. 
 All experiments using mice were approved by CNIO-ISCIII Ethics Committee for Research and 
Animal Welfare (CEIyBA). Pancreatic cancer xenografts Panc265, Panc198, Panc020, Panc042, 
Panc047, Panc026, Panc219 from our tumor bank collection were used for the study. These 
xenografts have been generated from freshly biopsied pancreatic patient tumor samples and 
propagated subcutaneously (s.c) into successive mouse generations [107]. Freshly collected s.c 
grown tumors were cut with a sterile scalpel into small pieces of 1–2 mm3 and embedded in 
matrigel solution. NSG mice (purchased from Charles River, reproduced in the CNIO animal 
facility or provided by Inés Martín-Padura from CNIC) were anesthetized using Isoflurane gas 
anesthesia and administered with Buprenorphine dosed at 0.2 mg/kg. The left abdominal part was 
shaved and the skin was sterilized with 70% ethanol. Using a sterile surgical microscissors, small 
incision was made in the upper left abdomen, and the pancreas was exposed. Small tumor pieces 
from each xenograft model were implanted into the splenic lobe of the pancreas using 6-0mm 
absorbable sutures (B. Braun). Mice were monitored during the whole study and they were 
humanely sacrificed after appearance of several or all of the following symptoms: big tumor size, 
loss of body weight, lethargy, dyspnea and/or pain. The date of sacrifice was recorded and the 
organs: spleen, orthotopic primary graft, liver, lung, mesenteric lymph nodes, kidney and brain 
were collected and preserved in 10% formalin solution for subsequent histological studies. For 
calculation of tumor volume, the short and long diameter of each freshly resected orthotopic tumor 
graft was measured by caliber and the tumor volume was calculated according to the following 
formula: 
Tumor volume = (short diameter
2 
x long diameter)/2 
3.2 Pancreatectomy procedure.  
The NSG mice harboring Panc265 orthotopic xenograft were anesthetized using Isoflurane gas 
anesthesia and administered with Buprenorphine dosed at 0.2 mg/kg. The left abdominal was 
disinfected with 70% ethanol. Using a sterile surgical microscissors, small incision was made in 
the upper left abdomen, and the pancreas harboring pancreatic tumor was exposed. Then, the 
healthy pancreas proximal to the tumor was ligated with a 6-0mm sutures and using a bipolar 
Spas Dimitrov Markov 
23 
 
electrocautery system, the cauterization was performed close to the tumor graft. After the 
cauterization, part of the splenic lobe of the pancreas and the whole spleen were resected with a 
sterile microscissors. The abdominal cavity was carefully explored for evidence of abdominal 
hemorrhage, and the abdominal incision was closed with a 6-0mm absorbable suture. The general 
health status and body weight of each mice were monitored during the whole study.  
 
3.3. Immunohistology. 
3.3.1. Hematoxylin and Eosin staining. 
The Comparative Pathology Unit at CNIO prepared the paraffin blocks from the mentioned above 
mouse tissues and generated 2.5-3 mm-thick sections, which were then deparaffinized, rehydrated 
and subjected to hematoxylin and eosin H&E staining. 
3.3.2. Immunohistochemistry: Survivin and Vimentin staining.  
Paraffin sections from some of the mentioned above tissues were subjected to deparaffinization 
and rehydration in graded ethanol washes. The CTCs isolated from metastatic PDX model were 
spun onto glass slides and fixed in 4% paraformaldehyde for 10 min at room temperature. Epitope 
retrieval was performed in an autoclave for 6 min (121°C) in sodium citrate buffer pH6 (Dako). 
Endogenous peroxidase activity was blocked by treatment with 3% hydrogen peroxide solution 
(Sigma Aldrich) for 10 min at room temperature. The slides were then blocked with 5% NMS for 1 
hour in RT and incubated with a monoclonal rabbit anti-Survivin antibody (clone EP2880Y, 
Abcam, dilution 1/250 in PBS1% and 1% normal goat serum), overnight at 4 °C. The detection of 
Survivin antibody was performed using Vectastain ABC kit (Vector labs) and developed with 
3,30-diamniobenzidine(DAB), according to the manufacturer's instructions. The slides were 
counterstained with hematoxylin, dehydrated in graded solutions of ethanol and mounted in DPX 
medium.  
Comparative Pathology Unit at CNIO performed the immunohistochemistry staining for vimentin 
using the human specific ready to use antibody (clone V9, DAKO) according to standard 
procedures. The slides were digitalized with the Axio Scan Z1 and representative images were 
captured with the Zen Software and brithless and contrast were adjusted with Photoshop software. 
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3.4. Immunofluorescence: 
3.4.1. Vimentin and GFAP staining. 
Mouse brains were harvested and fixed with 4% paraformaldehyde (PFA) at 4 C. The PFA fixed 
brains were washed with PBS1x (3 times) and dehydrated in sucrose (15% and then 30%). Slicing 
of the brain was done by using a sliding microtome with freezing stage. 80-nm thick brain slices 
were blocked in 10% NRS, BSA 2%, Triton 0.25% in PBS for 2 hr at room temperature (RT, 
shaking). Primary antibodies were incubated overnight at 4C, shaking. After extensive washing in 
PBS-Triton 0.25% (6 times), the secondary antibody was added in the blocking solution and 
incubated for (2 hr, RT, shaking). After extensive washing in PBS-Triton 0.25% (3 times) and in 
PBS1x (3 times), nuclei were stained with Bis-benzamide 1:1000 for 5 min at RT, shaking. 
Primary antibodies: anti-human vimentin (clone V9, DAKO), anti-mouse GFAP (poly-clonal, 
DAKO). The slides were mounted in fluorescence mounting medium (DAKO). Images were 
acquired with Leica SP5 upright confocal microscope, and analyzed with ImageJ software. This 
methodology was elaborated in accordance to the protocol provided by Dr. Manuel Valiente from 
CNIO. Manuel Valiente’s group performed the staining procedure. The representative images were 
acquired with the help of Dr. Manuel Valiente. 
 
3.4.2. Survivin staining. 
The CTCs isolated from metastatic PDX model were spun onto glass slides and fixed in 4% 
paraformaldehyde for 10 min at room temperature, followed by 3 washes in PBS1x for 5 min. 
The cells were then permeabilized with 0.1% Triton X-100 diluted in PBS1x for 10 min. The 
slides were blocked in 5% NGS and 5% NMS sequentially for 1 hour at RT. Primary antibodies 
for Survivin (1/100 dilution) were sequentially incubated overnight at 4C. After extensive washing 
in PBS, the secondary antibodies: Alexa-Fluor anti-rabbit
488
, anti-mouse
555
 (provided by Confocal 
Unit from CNIO) were diluted in PBS (1/200) and were then sequentially incubated for 1 hour at 
RT. After extensive washing in PBS, nuclei were stained with Hoechst (provided by Confocal Unit 
from CNIO) for 10 min at RT. The slides were mounted in fluorescence mounting medium 
(DAKO). Images were acquired with Leica SP5 upright confocal microscope, and prepared with 
Image J software. 
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3.5. In-situ Hybridization: Alu staining.  
Alu positive control probe II is a cocktail of dinitrophenol (DNP)-labeled oligonucleotide probes, 
which hybridized to Alu repetitive sequences present within the primate genome [108]. Tissue 
samples were fixed in 10% neutral buffered formalin (4% formaldehyde in solution), paraffin-
embedded and cut at 3 µm, mounted in superfrost®plus slides and dried overnight. For the whole 
technique an automated immunostaining platform was used (Ventana Discovery XT, Roche). 
Antigen retrieval was first performed with low pH buffer (RiboCC, Roche) and protease III 
(Roche). Slides were then incubated with the probe Alu positive control probe II (Ventana, Roche 
05272041001). After the probe, stringency washes were necessary three times and the slides were 
incubated with an intermediate, Rabbit anti-DNP. Visualization systems were needed 
(OmniRabbit, Ventana, Roche) conjugated with horseradish peroxidase; immunohistochemical 
reaction was developed using Silver, as a chromogen (Silver kit, Ventana, Roche) and nuclei were 
counterstained with Carazzi’s hematoxylin. Finally, the slides were dehydrated, cleared and 
mounted with a permanent mounting medium for microscopic evaluation. This protocol was 
elaboerated in accordance to the protocol provided by Histopathology Unit from CNIO. The Alu 
staining was performed by Histopathology Unit from CNIO.  
 
3.6. Quantitative PCR: targeting human DNA (Alu-sequences) in blood of metastatic PDX 
models. 
Fresh EDTA-blood was collected via a cardiac puncture from NSG mice implanted orthotopically 
with a highly metastatic Panc265 model. The blood from each animal was first centrifugated at 
400g for 10 minutes and the plasma was separated from the cellular pellet. Next, the cellular 
pellets were resuspended in 2 ml of red blood cell lysis solution (Qiagen, Cat. No.79217) for 10 
min at 37°C. The samples were then centrifuged for 7 min at 300 g, followed by two washing steps 
using 1 ml of sterile PBS1x. After the washing steps, the cellular pellets were resuspended in 
200µl of sterile PBS1x and the DNA extraction from each sample was performed using DNeasy 
Blood & Tissue Kit (Qiagen, Cat. No. 69504) following the manufacturer's instructions . The DNA 
was then eluted in 100µl of nuclease-free water. Finally, the DNA concentrations were measured 
using a NanoDrop ND-1000 spectrophotometer. 
Real‐time PCR using TaqMan® was performed on Real-Time PCR System 7500 (Applied 
Biosystems), according to the manufacturer's instructions. Oligonucleotide primers for Alu 
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sequences are [For 5′-GTCAGGAGATCGAGACCATCCT-3′ (position 68–90) `/Rev 5′-
AGTGGCGCAATCTCGGC- 3′ (position 244–227). The TaqMan® probe is 5′-6-FAM 
AGCTACTCGGGAGGCTGAGGCAGGA-TAMRA-3′ (position 167–192) [109]. The primers, 
probe and Taqman Universal PCR Master Mix were purchased from Applied Biosystems. 
PCRs were carried out in 20 μL following the manufacturer's instructions. Each sample was then 
subjected to an initial denaturation of 95°C for 10 min, followed by 40 amplification cycles of 
denaturation at 95°C for 15 s and annealing/extension at 60°C for 1 min. DNA from murine blood 
and water were used as negative controls. 
Data from the PCR experiments were exported from PCR system 7500 software (Applied 
Biosystems) into a Microsoft® Excel® spreadsheet where the mean value and standard deviation 
were calculated for each point on the standard curve. Using the Excel trendline option, a line of 
best fit was plotted with Y-error bars equal to the standard deviation. The Excel chart wizard was 
used to construct bar graphs with Y-bars equal to one standard deviation. 
3.7. Tissue dissociation. 
All solid mouse tissues were dissociated using a human tumor dissociation kit (Miltenyi Biotec) 
and a gentleMACS dissociator (Miltenyi Biotec) according to the manufacturer's instructions. The 
dissociated single-cell suspension was then passed through a 40-μm cell strainer (BD Biosciences) 
and resuspended in MACS cell sorting buffer (Miltenyi Biotec) to determine the cell number and 
viability using trypan blue dye, prior to further applications. 
For blood collection, tumor-bearing mice were bled using a 1 ml syringe via a cardiac puncture 
and collected in EDTA containing tubes. The blood was then diluted 1:1 with PBS1x, and 
carefully layered upon 1.5 volume of Ficoll‐Paque Plus (VWR International Eurolab) and 
centrifuged for 30 to 40 minutes at 400g, without brake, at room temperature. The mononuclear 
cell layer was then collected, washed in PBS1x, counted and prepared for further application. 
3.8. Flow cytometry.  
Antibodies for the human antigen HLA-ABC (clone G46-2.6, BD Pharmingen) and for mouse 
antigen H2kD (clone SF1-1.1.1, eBioscience) were purchased commercially. All antibodies were 
validated in this study directly. Antibody staining was performed in 1%PBS. After 20min at 4 °C, 
stained cells were washed of excess unbound antibodies. Forward-scatter height versus forward-
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scatter width (FSC-H versus FSC-W) and side-scatter area versus side-scatter width (SSC-A 
versus SSC-W) were used to exclude cell debris and aggregates. Dead cells were eliminated by 
excluding DAPI (4',6-diamidino-2-phenylindole) positive cells. Data were acquired on a BD 
FACSCanto and analyzed using FlowJo software. The flow cytometry analyses were performed in 
Flow Cytometry Unit from CNIO. 
3.9. Isolation of human tumor cells from metastatic PDX models.  
Human tumor cells from the mouse peripheral tissues were purified by autoMACS Pro Separator 
using MS columns (Miltenyi Biotec) in accordance with the manufacturer’s instructions. Before 
loading, the single-cell suspension was filtered through a 40-μm cell strainer (BD Biosciences). 
Human tumor cells were enriched by two-step process: first incubating with a PE-conjugated 
primary antibody for the human antigen HLA-ABC (clone G46-2.6, BD Pharmingen), followed by 
incubation with Anti-PE MicroBeads UltraPure (Miltenyi Biotec). The enriched human tumor 
cells were imaged using a confocal microscope (Leica SP5-MP). 
3.10. Single-cell RNA sequencing and processing.                                                                     
Tumor cells enriched from primary tumor, mouse blood and liver of PDX metastatic model were 
individually separated on the C1™ Single-Cell Auto Prep System (Fluidigm, South San Francisco, 
CA,USA)and cDNA amplification was generated using the SMARTer®Ultra™ Low RNA kit for 
the Fluidigm C1™ System (Clontech, Mountain View, CA, USA). In total, 137 cells were 
captured on three C1 array chips for mRNA sequencing (17–25 μmFluidigm). In total 84 samples 
passed the quality criteria. cDNA quantity and quality was measured with a 2100 Bioanalyzer 
(Agilent). Libraries were generated from 300 pg of amplified cDNA using the Nextera XT DNA 
Sample Prep Kit (Illumina) and sequenced on the HiSeq 2500 sequencer (Illumina) to generate 50 
bases single reads at a depth of 7.5–13.2 million reads. After single-cell sequencing, any putative 
murine cell was discarded by FastQ Screen software (v. 0.4.4) [110], which is able to detect 
mRNA sample reads that belongs to the human or to the mouse transcriptomes. The mRNA reads 
derived from human single cells were aligned on the human genome reference (hg19 assembly, 
UCSC) using the TopHat2 algorithm (v. 2.0.10) [111], retrieving the best hit with the default 
parameters, but allowing a maximum of five multi-hits with the same alignment score. The gene-
level expressions was quantified as the sum of all reads mapping on the exons for each gene 
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towards the gene annotation for the human genome (hg19, UCSC) using HTSeq-count (v. 0.5.4p5) 
[112]. The genomics experiments were performed by Genomics Unit from CNIC. Part of this 
methodology was elaborated by Genomics Unit from CNIC. 
3.11. Computational and statistical analysis of single-cell gene expression data. 
 
Statistical analysis. 
Genes with no expression data in all the cells from the study, which are either not expressed or 
dropped-out as an artifact of the single-cell RNA sequencing, were filtered out for further analysis. 
The R function prcomp was used to perform a principal component analysis (PCA) on the log2-
transformed single-cell gene expression profiles (read counts per million).  
 
The differential gene expression test based on read counts from single-cell RNAseq was carried 
out using SCDE (bioconductor R package, v. 1.99.4) [113], with the recommended parameters by 
the authors. The single-cell error/regression model was fit using all individual cells included in the 
study, and grouping by cell subpopulation at the first cross-comparison to extract the subset of 
genes with consistent expression within the subpopulation. Genome-wide tests for expression 
differences between the three cell subpopulations were performed by pairs, with the default 
parameters (1000 bootstrap randomizations). After adjusting p-values for multiple testing 
(Benjamini & Hochberg method) [114], genes with false discovery rate (FDR) < 0.05 were 
considered statistically significant. For PCA and differential gene expression analysis were only 
included DAPI-/HLA-ABC PE+ cells. 
 
A pre-ranked gene list by the Z-score of the expression difference between circulating tumour cells 
and primary tumour cells obtained by SCDE was used to perform Gene Set Enrichment Analysis 
using the GSEA Java Software (Broad Institute, v. 2.2.1) [115], with the default parameters 
(weighted Enrichment Score formula, 1000 permutations). Several gene set collections were tested 
to find biological insights: KEGG and Hallmark gene set collections from MSigDB (Broad 
Institute, v. 5.1), kinase substrates from Kinase Enrichment Analysis Library (KEA2015, 
downloaded from http://amp.pharm.mssm.edu/Enrichr/enrich). Additionally, custom gene sets for 
the selected drugs and their target genes were generated from the LINCS L1000 data set (described 
elsewhere), and used to further investigate drug candidates from the connectivity map analysis. 
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Gene sets with false discovery rate (FDR) < 0.05 were considered statistically significant [114].  
 
 
Computational anti-metastatic drug prescription. 
The in-silico anti-metastatic treatment prescription was carried out based on the Connectivity Map 
analysis, described in Lamb J. et al. 2006 [116]. Briefly, the connection of the gene expression 
signature of the biological transition of primary tumour cells to circulating tumour cells was 
interrogated against a comprehensive collection of gene expression signatures that represent 
cellular states of cell lines upon the transcriptional response to different types of perturbations 
(gene knock-down, gene over-expression and drug treatments). For this, The Library of Network-
Based Cellular Signatures (LINCS) L1000 data set (Broad Institute LINCS Center for 
Transcriptomics (1U54HL127366) [117]) provides a large-scale catalogue of transcriptional 
responses to pharmacological and genetic perturbations of a large panel of cell lines. The CLUE 
data portal analysis (http://www.clue.io, Broad Institute) was used for a broad search looking for 
opposing drug connections amongst the LINCS L1000 catalogue, using the top 100 most 
significantly up- and down-deregulated genes (by the z-score of the expression difference) from 
the differential gene expression between circulating tumour cells and primary tumour cells. To 
further investigate selected connections (drugs and target genes), consensus perturbation signatures 
of cell lines were generated from the LINCS level 3 data (quantile log2 normalized gene 
expression profiles) using limma (v. 3.24.15) [118], by comparing the differential gene expression 
between treated and untreated control experiments for a given perturbation, and using an additive 
linear model to block for cell line/batch effects across experiments (experiments that were done 
experimentally in different L1000 plates). Gene sets derived from the selected signatures were 
defined using the top 100 most up- and down-expressed by ranking the moderated-t statistic of the 
differential gene expression test. The computational analysis were performed by Bioinformatics 
Unit from CNIO. This methodology was elaborated by Bioinformatics Unit from CNIO. 
3.12. In vivo treatment experiments. 
 
3.12.1. Single cell-driven In-vivo treatment experiments. 
 
YM155(purchased from Selleckchem) was dissolved and diluted in saline, Danusertib(purchased 
from Medchem express) was dissolved in an in situ salt prepared as previously described [119] 
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and diluted in 5% dextrose, Abraxane was dissolved and diluted in saline, Pac-1(purchased from 
Medchem express) was dissolved in DMSO and diluted in saline prior to administration. For the 
single cell-driven In-vivo efficacy studies, the following drug treatment regimens were established: 
YM155 (2 mg/kg/d, i.v.) [120]; Abraxane (50mg/kg once a week, i.v.); PAC-1 (5 mg/kg/d, i.v) 
[121]; Danusertib (PHA-739358) (15 mg/kg/d, i.p.) [119]; PAC-1+Abraxane; YM155+Abraxane; 
Danusertib+Abraxane, 6-8 mice per group. The drug treatment course was initiated 1 week after 
implantation of Panc265 model. For early In-vivo treatment study with a highly metastatic 
Panc265 model, the treatment course with YM155 and Abraxane was initiated 2 and 3 days after 
tumor implantation , respectively. For In-vivo efficacy study with Panc198 metastatic model, the 
treatment course with YM155 and Abraxane was initiated 2 weeks after tumor implantation. The 
mice were treated during 4 weeks with all compounds and 3 weeks with Abraxane, monitored 
daily for signs of toxicity, and were weighed thrice a week. Animals that developed adverse effects 
(for example, 20% weight loss) were humanely euthanized and excluded from the study. After 
treatment period, small number of mice of Danusertib and/or YM155 treatment group were 
euthanized at the time of ethical endpoint sacrifice of control group and the rest mice were 
subsequently monitored and sacrificed when they manifested the mentioned above signs of 
sickness. For evaluation of metastatic tumor burden in Panc265 metastatic model, mouse livers 
and lungs of control and treatment groups (Danusertib and/or YM155) were subjected to Alu-
staining and the percentage of Alu-positive cells was determined by Axio Vision. Kaplan–Meier 
survival plots were prepared using GraphPad software and median survival times were determined 
for all experimental groups. 
 
3.12.2. Withaferin-A treatment experiment: 
Withaferin-A (WFA) (purchased from Enzolifesciences) was dissolved in DMSO and dilute in 
saline prior to administration. Panc265 bearing mice were randomly assigned to two treatment 
groups (6 mice per group): (1) Control; (2) WFA (2 mg/kg/d, i.p.). The drug treatment course was 
initiated 1 week post-implantation. Mice were treated during 28 days, monitored daily for signs of 
toxicity, and were weighed thrice a week. After treatment period, all mice were subsequently 
monitored and sacrificed when they showed the mentioned above signs of sickness. Histological 
sections of mouse liver and lung were examined microscopically for presence of metastases in all 
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animals of each group. Kaplan–Meier survival plots were prepared and median survival times 
were determined for all experimental groups. 
 
3.13. Proteomic analyses of the exosomes derived from metastatic PDX models. 
 
Sample Preparation. 
The exosomes from primary tumors and metastatic organs of each PDX model were purified and 
prepared by Hector Peinado’s group at CNIO. Exosomes from PDAC, lung and liver explants 
were quantified using the Qubit platform (Life Technologies). The equivalent to 15 ug of each 
sample was loaded onto unit filters and digested according to the FASP protocol
1
 with some 
changes. Samples were made up to 250 uL with 8M urea 0.1M Tris-HCl pH=8 solution (UT 
buffer). Then the proteins were reduced with 15 mM TCEP for 30 min at RT and alkylated with 
15mM CAA for 30 min in the dark. After several washes with UT buffer, proteins were doubly 
digested with LysC (Wako) overnight at RT and with Trypsin (Promega) for 5 h at 37ºC at a ratio 
1:50 (enzyme: substrate) in 0.1M Tris-HCl. Resulting peptides were further desalted and 
concentrated using homemade reversed phase micro-columns filled with Poros Oligo R3 beads 
(Life Technologies), containing a C18 Emporedisk (3M) at the bottom of the tip. The samples 
were dried using the Speed-Vac and dissolved in 30 µL of loading buffer (0.2% FA).  
 
LC-MS/MS analysis. 
Peptides were separated by reversed-phase chromatography using a nanoLC Ultra system 
(Eksigent), directly coupled with a LTQ-OrbitrapVelos instrument (Thermo Fisher Scientific) via 
nanoelectrospray source (ProxeonBiosystem). Peptides were loaded onto the column (Dr. Maisch, 
ReproSil-Pur C18-AQ GmbH 2.4µm, 500x0.075 mm), with a previous trapping column step (NS-
MP-10 BioSphere C18 5 µm 120Å 360/100 µm, L=20 mm, Nanoseparations), during 10 min with 
a flow rate of 2.5 µl/min of loading buffer (0.1% FA). Elution from the column was made with a 
120 min linear gradient (buffer A: 4% ACN, 0.1%FA; buffer B: 100% ACN, 0.1%FA) at 250 
nL/min. The peptides were directly electrosprayed into the mass spectrometer using a PicoTip 
emitter (360/20 OD/ID µm tip ID 10 µm, New Objective) a 1.4 kV spray voltage with a heated 
capillary temperature of 325°C and S-Lens of 60%. Mass spectra were acquired in a data-
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dependent manner, with an automatic switch between MS and MS/MS scans using a top 20 
method with a threshold signal of 800 counts. MS spectra were acquired with a resolution of 
60000 (FWHM) at 400 m/z in the Orbitrap, scanning a mass range between 350 and 1500 m/z. 
Peptide fragmentation was performed using collision induced dissociation (CID/CAD) and 
fragment ions were detected in the linear ion trap. The normalized collision energy was set to 35%, 
the Q value to 0.25 and the activation time to 10 ms. The maximum ion injection times for the 
survey scan and the MS/MS scans were 500 ms and 100 ms respectively and the ion target values 
were set to 1E6 and 5000, respectively for each scan mode. Samples were randomly injected and 
analysed in duplicates. A quality control was run every 6 samples to check system performance. 
 
Data analysis. 
Raw files were analyzed either by Proteome Discoverer (version 1.4.1.2) or by 
MaxQuant
2
(v1.5.3.30) against a forward-reverse concatenated database. The database included 
human and mouse proteins (UniProtKB/Swiss-Prot20,187 and UniProtKB/Swiss-Prot/TrEMBL 
43,539 sequences, respectively) and common contaminants. Human accession numbers were 
taggedin order to differentiate protein matches from each organism, when possible. 
Carbamidomethylation of cysteineswas considered as fixed modificationwhereas oxidation of 
methionines was set as variable modifications in both SequestHT and Andromeda search engine 
(v2.2). SequestHT, in conjunction with Percolator provided the list of proteins for Proteome 
Discoverer. Minimal peptide length was set to 6 amino acids and a maximum of two missed-
cleavages were allowed. Peptides were filtered at 1% FDR. For protein assessment in MaxQuant, 
at least one unique peptide provided by Andromeda search engine
3
 with a FDR = 1% was required 
for both identification and quantification. Other parameters were set as default. Afterwards, the 
“proteingroup”filewasuploadedinPerseus4 (v1.5.5.2). After removing proteins annotated as 
contaminants, only identified by site and/or reversed, the missing values of the matrix were 
imputed as a normal distribution assuming low intensity values. Then, a Welch t-test analysis (p 
value 0.05, FDR 0.01) was performed on proteins present in 70% of the samples of at least one of 
the 2 groups. Only significant proteins with a fold-change above 1.5 (log2) were considered as 
regulated. Protein classification enrichment analysis (molecular function, biological process and 
protein class) was performed by PANTHER software, using the entire list of identified proteins as 
the reference data set to analyse the regulated proteins. This methodology was provided by 
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Proteomics Unit from CNIO. The proteomics experiments and analysis were performed by 
Proteomics Unit from CNIO. 
3.14. Statistical analyses. 
An unpaired two-tailed t test was applied to calculate the statistical significance of Alu-positive 
cells between control and drug treated groups; to calculate the statistical significance of tumor 
weights between control and YM155 treated group; to calculate the statistical significance of the 
human DNA level in the mouse blood at different time points using a Graphpad software. 
  
A log-rank test (Mantel-Cox) was applied to determine the statistical differences in the survival 
curves of the animal experimental groups. Differences were considered statistically significant at P 
value < 0.05. Statistical significance is indicated by * (p < 0.05), ** (p < 0.001) and *** (p < 
0.0001). 
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IV. RESULTS. 
 
4.1. Metastatic PDX models of pancreatic cancer. 
 
4.1.1. Choice of a recipient mouse strain for modeling the metastatic disease. 
A first decisive choice for establishment of an In-vivo metastasis model was the one of the 
recipient mouse strain. Several immunocompromised strains have been developed during the past 
years. Three immunocompromised mouse strains (Nude, SCID and NOD/SCID/IL2g (NSG) mice) 
were studied and compared for their suitability as a models for experimental metastasis. Nude 
mice are homozygous for the nude spontaneous mutation (Foxn1
nu
, formerly Hfh11
nu
). They are 
characterized by abnormal hair growth and defective development of the thymic epithelium. These 
mice lack T cells and suffer from a lack of cell-mediated immunity. Homozygous nude mice show 
partial defect in B cell development. In contrast, the SCID mice possess a genetic autosomal 
recessive mutation (SCID). This mice strain show a severe combined immunodeficiency affecting 
both B and T lymphocytes. They have normal natural killer (NK) cells, macrophages, and 
granulocytes. On the other hand, NSG mice are double homozygous for the severe combined 
immunodeficiency (SCID) mutation and for the allelic mutation of the common gamma chain of 
the interleukin‐2 receptor (IL-2RG) [122]. These mice are functionally incompetent for B, T and 
NK cells, and are deficient in cytokine signaling. 
 
 In order to determine which of these immunocompromised strains would be better recipients for 
the experimental metastasis assay, various PDAC xenografts were implanted orthotopically and 
the metastatic incidence of each xenograft model was compared between the three mouse strains. 
High metastatic incidence was observed in NSG mice strains, however no metastatic lesions were 
detected in Nude and Scid mice (Figure7, Table3), indicating that NSG mice are more permissive 
recipients for establishment of In-vivo metastasis models. In contrast to NSG mice strain, both 
Nude and Scid mice have functional NK cell, macrophages and dendritic cell, suggesting that the 
immune status of host mice strain could have an important impact on tumor dissemination and 
establishment of distal metastasis. 
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Figure 7. Choice of a Xenograft recipient for modeling the metastatic disease. Representative 
photomicrographs of Alu In-situ hybridization (Alu ISH) of liver and lung tissues obtained from 
metastatic Panc265 and Panc042 model implanted orthotopically in Nude, Scid and NSG mice. 
The red arrows indicate the Alu-positive human tumor cells in mouse lungs. The silver staining 
corresponds to human nuclei, in which the Alu probe hybridizes (scale bar 50µm). The lung slide 
Spas Dimitrov Markov 
36 
 
of Panc042 model was counterstained with eosin staining. (Table 3) - Summary table of metastatic 
incidence in PDX models. 
 
4.1.2. Development of Metastatic PDX model of pancreatic cancer. 
In order to develop an in-vivo metastatic model that recapitulates the metastatic disease, we 
implanted several pancreatic cancer xenografts from our tumor bank (Panc265, Panc198, Panc020, 
Panc026, Panc042, Panc047, Panc219) orthotopically into severely immunocompromised NSG 
mice. Upon orthotopic transplantation, Panc265 xenograft model exhibits aggressive metastatic 
behavior and results in massive liver and lung metastasis in all mice with median survival rate of 
25 days (Figure8A, 8D, Table 4). Sporadic brain micrometastasis on single-cell level has been also 
detected in Panc265 metastatic model by In-situ hybridization for primate ALU sequences 
(Figure8B). Moreover, Immunofluorescence staining using human-specific antibody against the 
vimentin protein (expressed by the tumor cells, discussed below) detected small cluster of human 
metastatic cells in brain parenchyma, surrounded by GFAP-positive reactive astrocytes 
(Figure8B), which activation is considered as a hallmark of brain metastasis[123]. At late stages of 
tumor progression, Panc265 bearing mice displayed signs of lethargy, significant lost of body 
weight and respiratory insufficiency. 
  
Panc198 is the second metastatic model, which was able to establish liver and lung metastasis in 
all mice with median survival rate of 54.5 days (Figure8A, 8D, Table 4). The other fifth metastatic 
models Panc020, Panc026, Panc042, Panc047 and Panc219 gave rise only to lung micrometastasis 
in all implanted mice with different survival rates (Figure8C, 8D, Table 4). The mice of these 
models were often sacrificed due to primary tumor size and respiratory insufficiency. The presence 
of human tumor cells in host liver and lung was detected by In-situ hybridization to primate ALU 
sequences (Figure8A, 8C). In total, we generated seven metastatic PDX models with high 
metastatic incidence, model-specific dissemination pattern and distinct survival rates. For 
subsequent studies, we mainly focused on Panc265 model, since it showed the most aggressive 
phenotype with the shortest survival rate. 
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Figure 8. Development of metastatic PDX models of pancreatic cancer. (8A) – Left vertical 
panels - Representative photomicrographs of Hematoxylin and Eosin (H&E) staining of tumor, 
liver and lung tissues derived from metastatic PDX models (Panc265, Panc198). The black arrows 
indicate the metastatic lesions in mouse livers and/or lungs. Right vertical panels – Representative 
photomicrographs of Alu ISH of a tumor graft, liver and lung sections - the silver staining 
corresponds to human nuclei, in which the Alu probe hybridizes (scale bar 50µm) (8B) – Left 
panel - Representative photomicrographs of Alu ISH of a brain section derived from a highly 
metastatic Panc265 model. Right panel - Representative immunoflourescence image of human 
vimentin (red) and mouse GFAP (green). (8C) - Left vertical panels - Representative 
photomicrographs of Hematoxylin and Eosin (H&E) staining of tumor, liver and lung tissues 
derived from metastatic PDX models (Panc020, Panc026, Panc042, Panc047, Panc219). The black 
arrows indicate the metastatic lesions in mouse livers and/or lungs. Right vertical panels – 
Representative photomicrographs of Alu ISH of a tumor graft, liver and lung sections (scale bar 
50µm). (8D) - Kaplan-Meier plot of metastatic PDX models. (Table 4) - Summary table of 
metastatic incidence in PDX models.  
4.1.3. Human vimentin expression predicts the occurrence of metastasis in PDX orthotopic 
models of pancreatic cancer. 
4.1.3.1. Assesment of vimentin protein expression in metastatic and non-metastatic PDX 
models of pancreatic cancer. 
In this study, we evaluated the human vimentin expression in a series of PDX models of PDAC 
with metastatic and non-metastatic In-vivo capacity. Interestingly, 6 out of 7 metastatic PDX 
models were positive for human vimentin marker (Figure 9A). More interestingly, the metastatic 
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lessions of these six metastatic PDX models also contain vimentin-positive tumor cells (Figure 
9A). The models with higher vimentin expression are characterized by poor histological 
differentiation, aggressive metastatic phenotype and shorter survival rate (Figure 9 A, B, C), 
which is in agreement with the previously reported findings showing that vimentin expression is 
associated with poor prognosis[124-132]. Moreover, the vimentin expression pattern in two PDX 
models is consistently similar to the pattern of their corresponding human tumor specimens 
(Figure 9B), which is consistent with previous reports that the PDX models preserve essential 
properties of the original tumors. We also evaluated the vimentin expression in a series of non-
metastatic PDX models and found that 2 out of 4 non-metastatic models were vimentin negative 
and one model with low vimentin expression (Figure9C, Table5). Only Panc059 non-metastatic 
model was characterized by high vimentin expression, fast-growing tumors and short survival rate 
(Figure 9B,D). Together these results suggest that (1) - Vimentin could serve as a predictive 
marker for In-vivo metastatic potential of PDAC xenograft tumors; (2) - It could play an important 
role in pancreatic cancer metastasis. 
Spas Dimitrov Markov 
41 
 
                        
Spas Dimitrov Markov 
42 
 
                            
Spas Dimitrov Markov 
43 
 
                                
                              
 
Figure 9. Evaluation of Vimentin expression in metastatic PDX models of pancreatic cancer. 
(9A) – Representative images of immunohistochemistry (IHC) staining for vimentin in tumor, 
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liver and lung tissues of metastatic PDX models (scale bar 50µm). (9B) – Representative images 
of IHC staining for vimentin in human pancreatic tumor specimens (Panc020 and Panc059) and 
their corresponding xenograft models. (9C) – Representative images of IHC staining for vimentin 
in tumor xenografts of non-metastatic PDX models (scale bar 200µm). (9D) - Kaplan-Meier plot 
of non-metastatic PDX models. (Table 5) - Summary table of vimentin expression and survival 
days of non-metastatic PDX models. Survival data were analyzed using GraphPad Prism 6 
software. 
4.1.3.2. In-vivo efficacy study with Withaferin-A in a highly metastatic Panc265 model. 
To investigate whether vimentin could be an anti-metastatic target, we carried out an In-vivo 
efficacy study with the highly aggressive Panc265 metastatic model, evaluating the effect of 
Withaferin-A (a natural product shown to decrease vimentin protein expression in MDA-MB-231 
xenografts and MMTV-neu tumor in vivo) [133] on metastasis formation and survival. Mice 
bearing orthotopically engrafted tumors were divided in two groups and treated with vehicle and 
WFA. The results demonstrated that WFA showed no significant increase in survival compared to 
vehicle treated mice (Figure10A). Furthermore, the H&E stained sections of mouse liver and lung 
organs of each treatment group were carefully examined and it was observed that 100% of vehicle 
and WFA treated animals had massive metastatic lesions in the liver and lung organs (Table 6). To 
assess whether WFA had an effect on decreasing the expression of vimentin at protein level, the 
tumors and distal organs of WFA treated mice were stained for human vimentin. The results 
showed abundant vimentin expression in primary tumor, liver and lung metastatic lesions, equal to 
that of control group (Figure10B). This study demonstrated that WFA compound was inefficient to 
reduce the metastatic tumor burden and to increase the survival of the animals, therefore new 
strategies are needed to prove whether vimentin plays a pivotal role in pancreatic cancer spreading. 
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Figure 10. Efficacy study of Withaferin-A in Panc265 metastatic model. (10A) - Kaplan–
Meier survival curves of control and drug treated groups. (Table 6) - Summary table of metastatic 
incidence in PDX models. (10B) - Representative images of IHC staining for Vimentin in tumor 
graft, liver and lung derived from treated group (scale bar 50µm). Survival data were analyzed 
using GraphPad Prism 6 software. P-values for survival differences were calculated using the log-
rank (Mantel-Cox) test. 
 
4.1.4. Evaluation of metastatic progression in a highly metastatic Panc265 model. 
In order to monitor the primary growth, metastatic tumor burden and CTCs kinetics, we 
performed a time-course experiment of a highly metastatic Panc265 model. Groups of three mice 
were sacrificed periodically starting as early as 1 week after tumor implantation and primary 
tumor, metastatic organs and blood were collected at each time point. Alu-positive human cells in 
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mouse liver and lung organs have been detected as early as 2
nd
 week post-tumor implantation and 
their number increased exponentially at later time points (Figure 11A,B). Using a RT-PCR 
specific for human Alu sequences, a significant increase in human DNA level in mouse blood was 
detected at 3
rd
 week after tumor implantation and its level increased exponentially at 4
th
 week time 
point (Figure 11C).  
The results from this study demonstrated that the increased levels of human DNA in mouse blood 
at 3
rd
 and 4
th
 week correlated quite nicely with the primary tumor growth kinetics (Figure 11D) 
and with the increase of Alu-positive metastatic cells in mouse liver and lung organs (Figure 11B). 
However, there is still room for improvement in CTCs detection at early points of disease 
progression. One possible explanation for the failure to detect the human CTCs-derived DNA at 
1
st
 and 2
nd
 week could be the application of Red blood cell (RBC) lyses solution prior to DNA 
extraction from the mouse blood samples. In subsequent studies, we observed that the usage of 
hypotonic solutions to remove the RBC resulted in significant lost of the human CTCs. This 
observation is in agreement with previous studies, reporting that hemolysis of RBC is associated 
with deleterious hypotonic damage and loss of CTCs [134-136]. 
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Figure 11. Time-course experiment of a highly metastatic PDX model. (11A) – 1st and 3rd 
vertical panel – Representative Photomicrographs of H&E staining of liver and lung sections 
derived from a highly metastatic Panc265 model from 1
st
 to 4
th
 week after tumor implantation, 
respectively. 2
nd
 and 4
th
 vertical panel – Alu ISH of liver and lung sections obtained from 1st to 4th 
week after tumor implantation, respectively (scale bar 50µm). The red arrows indicate the Alu-
positive human tumor cells in mouse lungs. (11B) - Percentage of Alu+ positive human tumor 
cells relative to the total cell number in mouse livers and lungs resected from 1
st
 to 4
th
 week. (11C) 
– RT-qPCR quantification of human DNA in blood of PDX metastatic model at different time 
points. (11D) - The growth curve graph shows the primary tumor volume from 1
st
 to 4
th
 week. * (p 
< 0.05), *** (p < 0.0001). 
 
4.1.5. Identification and isolation of human tumor populations from metastatic PDX models. 
To identify the human tumor cells from metastatic PDX models, we checked the expression of 
MHC class I (HLA-ABC) antigen in two of our metastatic PDX models (Panc265, Panc198). This 
surface antigen is expressed on the surface of all nucleated cells and it is commonly used marker 
for identifying human cells in PDX models [137-138]. By Flow Cytometry, we identified that 
HLA-ABC is expressed by 83-86% of the tumor cells dissociated from Panc265 and Panc198 
xenograft models with negletable background in control mouse peripheral tissues 
(Figure12A,B,C). For identification of infiltrating mouse cells in xenograft tumors, we used H-
2kD marker (mouse MHC class I), which is expressed on the surface of all mouse nucleated cells. 
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To isolate viable human tumor cells from the mouse organs of metastatic PDX models, we 
performed magnetic-activated cell sorting (MACS) assay, where we applied a two-step process 
using a human specific HLA-ABC antibody to recognize the human tumor cells and anti-
flourochrome magnetic beads, which specifically recognize the flourochrome of primary antibody. 
By this approach, we were able to capture and purify the majority of primary tumor cells, CTCs 
and metastatic cells from the mouse organs of metastatic PDX model (Figure12D). 
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Figure 12. Identification of human metastatic cells in metastatic PDX models. 
 
 (12A) - FACS plots show fluorescence-minus-one (FMO) controls of H-2kD and HLA-ABC and 
the percentage of human HLA-ABC and mouse H-2kD cells in dissociated tumors of Panc265 
model (left to right, respectively). (12B) - FACS plots show fluorescence-minus-one (FMO) 
controls of H-2kD and HLA-ABC and the percentage of human HLA-ABC and mouse H-2kD 
cells in dissociated tumors of Panc198 model (left to right, respectively). (12C) - FACS plots show 
the percentage of HLA-ABC cells in pancreas, liver and lung dissociated tissues derived from 
naive mice. (12D) - Representative photomicrographs of HLA-ABC positive human tumor cells 
isolated by magnetic separation from tumor graft, liver and blood of a highly metastatic PDX 
model. 
 
4.1.6. Tumorigenic and metastatic capacity of CTCs derived from metastatic PDX model. 
To evaluate whether the CTCs derived from metastatic PDX model possess tumorigenic capacity, 
we isolated the human CTCs utilizing anti-human HLA-ABC antibody from the blood of a highly 
metastatic Panc265 model and subcutaneously injected 10000 and 5000 cells in one of the flanks 
of a NSG mice. Remarkably, we detected measurable tumors in 7 out of 8 transplants within a 
month after implantation and all of them produced large tumors reaching a volume of 1300 mm
3
 
(Figure 13A-B, Table 7). The histopathology and immunohistochemistry (IHC) of CTC-derived 
tumors and their corresponding parental primary tumor was also evaluated. We observed similar 
morphological pattern between primary and CTCs derived tumors, with neoplastic cells 
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characterized by moderate to severe nuclear pleomorphism with large bizarre nuclei and aberrant 
mitosis. CTC-derived tumors also display high expression of vimentin, consistent with the 
expression pattern of parental tumor (Figure 13D). 
To determine whether CTC-derived tumors also exhibit metastatic potential, we examined the 
livers and lungs of the tumor-bearing animals. Although no macrometastases were observed on 
visual inspection, subsequent histological examination of liver and lung sections revealed 
micrometastatic clusters of tumor cells in pulmonary parenchyma in all implanted mice and one 
sporadic liver micrometastasis (Figure 13C, Table 8). The human origin of CTC-derived tumors 
and their corresponding metastasis was confirmed by Alu staining (Figure 13C). Altogether, these 
findings support the hypothesis that CTCs population contain cells with tumor-initiating and 
metastasis-initiating properties [139-140].   
 
Spas Dimitrov Markov 
52 
 
     
 Figure 13. Human pancreatic CTCs possess tumor-initiating and metastatic capacity. (13A) 
- Representative photographs of mice carrying a subcutaneous CTC-derived tumor. The orange 
arrow indicate the CTC-derived tumor graft. (Table 7) - Summary table of tumor take rate after 
CTCs implantation. (13B) - Tumor volume over time after implantation with CTCs (5x10
3 
and 
1x10
4 
cells) isolated from Panc265 metastatic PDX model. (13C) – Left vertical panel- H&E 
staining of tumor, liver and lung tissues obtained from mice bearing CTCs derived tumors. The 
black arrows indicate the metastatic lesions in mouse liver and lung. Right vertical panel- Alu ISH 
of tumor graft and metastatic lesions in mouse liver and lung (scale bar 50µm). (Table 8) - 
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Summary table of metastatic incidence in CTCs bearing mice. (13D) - Representative images of 
immunohistochemistry (IHC) staining for vimentin in tumor graft of CTC derived tumor.  
4.2. Single-cell RNA sequencing of the human pancreatic tumor populations involved in 
metastatic disease. 
 
To investigate the transcriptional heterogeneity during the metastatic progression, we performed 
single cell RNA-seq to profile individual pancreatic tumor cells isolated from primary tumor graft, 
mouse blood and liver of one of our highly metastatic Panc265 model. An automated microfluidic-
based platform (Fluidigm) was used to capture and lyse individual human PDX tumor cells, 
followed by reverse transcription of mRNA and amplification of complementary DNA. We 
successfully sequenced 37 human primary tumor cells, 23 metastatic tumor cells and 10 CTCs to a 
depth of 7.5–13.2 million reads, of which 86.4%–89.5% uniquely aligned to the human reference 
genome, which is comparable to the mapping rates of other single cell RNA-seq data (Figure 14A, 
Table 9). The average number of expressed genes detected across single cell RNA seq analysis 
was above 8000 genes in primary and liver metastasis tumor cells and above 3000 genes in CTCs 
(Figure 14B), thus suggesting that CTCs display a degree of transcriptional repression compared to 
primary and metastatic cells. 
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Figure 14. Single-cell RNA-seq of tumor cells isolated from a highly metastatic PDX model. 
(14A) – Photomicrograph of single tumor cell captured on Integrated Fluidic Circuit (IFC) (10x). 
(Table9) – Summary table of single-cell RNA seq performance including the number of 
sequenced cells, average read counts and mapping (14B) - Represantative graph of number of 
expressed genes across single-cell analysis.  
 
4.2.1 Deciphering the transcriptional intra-tumoral heterogeneity during metastatic 
progression. 
 
In collaboration with Bioinformatics Unit from CNIO, we compared the gene expression profiles 
of all sequenced human tumor cells and the differential gene expression analysis revealed a small 
number of genes that were differentially expressed (FDR<0.05) between primary tumor, CTCs and 
liver metastasis cells (Table S2, S3, S4). To further investigate the gene expression signatures of 
the human PDX cells, we applied principal component analysis (PCA), which is the most widely 
used method for reduction of dimensionality of the data, and it has been effectively used in a 
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number of single-cell genomics studies. Remarkably, PCA clusters all sequenced human tumor 
cells into three distinctive main clusters: CTCs, primary and metastatic tumor cells (Figure 15). 
The first principal component separates the CTCs from primary and liver metastatic cells. The 
second principal component separates primary tumor cells from liver metastasis cells. Together, 
these results demonstrate that single-cell RNA-seq enables the identification of three biological 
groups with a high degree of intratumor heterogeneity, mostly pronounced in the CTCs. 
           
 
Figure 15. Principal component analysis (PCA) of single cells based on the two first principal 
components. PCA of primary tumor, liver metastasis and CTCs at single cell level. of single cell 
level. Brown: Primary tumour cells (n=37), light blue: liver metastasis cells (n=23), light green: 
Circulating tumour cells (n=10). 
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To further characterize the aspects of this transcriptional heterogeneity, we employed a recently 
published approach, called PAGODA [141], that resolves the transcriptional diversity at single-
cell level. This method identified that ECM interaction and focal adhesion, cell cycle and ribosome 
biogenesis are the main pathways differentially expressed among the single-cell populations 
(Figure 16). The first pattern separates the primary tumor cells from the CTCs and metastatic cells, 
based on increased expression of fibronectin1 (FN1), integrin subunit beta 5 (ITGB5), collagen 
type I alpha 1 chain (COL1A1) among others known markers of ECM interaction. The second 
major aspect is driven by a gene set associated with cell cycle, which is highly expressed in 
metastatic cells and subpopulation of primary tumor cells. To further dissect the cell cycle states, 
we employed a computational analysis [142] using annotated signatures for each phase of the cell 
cycle (G1, S, G2/M). Interestingly, the primary tumor and metastatic cells were similarly 
distributed between the cell cycle phases with higher frequency of cells in G1 and G2/M phase 
(Figure17). In contrast, the vast majority of CTCs were primarily allocated to G1 phase. Therefore, 
these results show that the primary tumor and metastatic group are composed of a large proportion 
of actively cycling cells, while the CTC group might be characterized by quiescent or slow-cycling 
cells with prolonged interphase. The third pattern reflects Ribosome signature, which is most 
pronounced in CTCs with high expression of ribosomal protein L38 (RPL38), ribosomal protein 
S16 (RPS16), ribosomal protein S29 (RPS29) among others common markers (Figure 16). 
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Figure 16. Deciphering the most important patterns of transcriptional heterogeneity.  
Heatmap of significant gene set patterns of transcriptional heterogeneity obtained by Pathway and 
Gene Set Overdispersion Analysis (PAGODA method; P < 0.05) using KEGG pathways. 
Significant patterns: 1=ECM receptor interaction and Focal adhesion. 2=Cell cycle. The 
dendrogram shows overall clustering of individual cells using biological pathways, brown= 
primary tumor cells, lightblue= Liver metastasis, lightgreen = CTCs. 
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Figure 17. Cell cycle allocation of the human tumor populations isolated from metastatic 
PDX model.                                                                                                                                
(17) - Cell-cycle phase distribution of human tumor populations isolated from metastatic PDX 
model. 
4.2.2. Identification of potential anti-metastatic targets for pancreatic cancer. 
 Next goal of the thesis was to identify potential anti-metastatic targets such as metastasis-
associated genes or pathways, which are deregulated in the CTCs (precursors of metastatic 
disease) with aim to find and test new therapeutic strategy that could inhibit pancreatic metastasis. 
In order to find potential anti-metastatic candidates, we decided to interrogate the gene expression 
profile of the human CTCs isolated from one of the metastatic PDX models. Interestingly, we 
found that the gene baculoviral IAP repeat containing 5 (BIRC5), also known as Survivin, is 
significantly up-regulated in CTCs (a 3.2 log2 fold change, FDR=0.02) in comparison to primary 
tumor profile (Table S1). BIRC5 is cancer-related gene, which belongs to the inhibitor of apoptosis 
family (IAP) and to chromosomal passenger complex involved in regulating chromomal 
segregation and cytokinesis during mitosis.  
To identify other potential anti-metastatic therapeutic targets, we also employed a connectivity 
mapping approach, which uses gene-expression profiling to connect genes, disease and drugs. 
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This method is a powerful tool to identify potential therapeutic drugs that are able to alter the gene 
expression signature of particular biological conditions [116]. Interestingly, drug connectivity map 
analysis using the gene expression signatures of primary tumor cells and CTCs showed that aurora 
kinase A (AURKA), aurora kinase B (AURKB) and polo like kinase 1 (PLK1) knock-down 
signatures had opposite connections and their kinase substrates were over-expressed in CTCs 
compared to primary tumor cells (Figure 18A, Table 10). Moreover, the top opposite drug 
signatures are enriched on various aurora kinase inhibitors including Danusartib (Table 11). This 
approach also revealed an enrichment of anti-apoptotic state in CTCs and the top most opposite 
drug compound was PAC-1 (promoter of caspase signaling) (Table 11).  
 
    
 
Figure 18. Identification of potential anti-metastatic targets for pancreatic cancer.  
(18A) - Enrichment of kinase substrates of AURKA, AURKB and PLK1 towards up-regulation in 
CTCs. (Table 10) - Opposite connection of AURKA, AURKB and PLK1 knock-down signatures 
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(source: LINCS L1000) in the gene expression signature from the biological state of CTCs vs. 
primary tumour cells. (Table 11) - Connectivity map statistics on the selected drug compounds for 
further drug efficacy studies. ES:Enrichment score; NES: Normalized Enrichment Score; NOM p-
val: Nominal p-value. FDR q-val: False Discovery Rate.  
 
4.2.3. In-vivo validation of single cell-driven therapeutic strategy. 
To validate whether targeting the previously identified candidates could have an In-vivo anti-
metastatic effect, we chose to test the following compounds: YM155 (small-molecule 
transcriptional repressor of Survivin, currently undergoing phase II clinical trials in patients with 
various types of cancer), Danusertib (a small molecule pan-aurora kinase inhibitor, currently in 
phase II clinical trials for treatment of patients with solid tumors) and Pac-1 (a small molecule that 
activates procaspase-3 to caspase-3, resulting in apoptosis of cancer cells, currently in phase 1 
clinical trials for the treatment of patients with advanced malignancies). Danusertib and Pac-1 are 
the top opposite drug signatures compounds identified by connectivity mapping analysis. 
 
 To evaluate the In-vivo effect of selected treatment regimens on metastasis formation and 
survival, mice implanted with a highly metastatic Panc265 model were randomized to the 
following experimental groups: (1) Control; (2) YM155; (3) PAC-1; (4) Danusertib; (5) PAC-
1+Abraxane (Abx); (6) YM155+Abx; (7) Danusertib+Abx; (doses and schedule are described in 
material and methods). The Abraxane arm was included in order to control the primary tumor 
growth and to evaluate whether the combo treatment will result in improvement in median survival 
compared with monotherapy regimens. One week post-implantation, the experimental groups were 
subjected to a 4-week treatment course. The results showed that upon completion of the treatment, 
Pac-1 monotherapy failed to demonstrate a significant increase in survival of the mice compared to 
control group. However, YM155 and Danusertib monotherapy significantly improved the median 
survival of treated animals compared to control animals (Figure 19A, Table 12). Pac-1 + ABX 
treatment resulted in a median survival of 40 days, but there was no significant difference in 
comparison to the median survival of YM155 and Danusertib single agent (Figure 19A, Table 12). 
Both YM155 + ABX and Danusertib + ABX showed a slightly significant improvement in median 
survival compared with YM155, Danusertib and Pac-1+ABX treatment groups (Figure 19A, Table 
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12). At the survival endpoint, the tumor-bearing mice of all treated groups displayed the usual 
signs of sickness (described in methods) caused by the progression of metastatic disease. 
 
Next, we evaluated the metastatic tumor burden of YM155 and Danusertib treated animals 
sacrificed at the survival endpoint of control group. The results showed that while Danusertib 
treatment failed to reduced significantly the metastatic tumor burden, treatment with YM155 
significantly decreased the percentage of the human metastatic cells in the liver and lung organs of 
drug treated group compared to control animals (Figure 19B,C).  
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Figure 19. In-vivo validation of single cell-driven therapeutic strategy. (19A) – Treatment 
course in PDX mice harbouring a highly metastatic Panc265 model (top). Kaplan–Meier survival 
curves of control and drug treated groups. (Table 12) - The table shows the median survival days 
and statistical significance of the experimental groups. Survival data were analysed using 
GraphPad Prism 6 software. P-values for survival differences were calculated using the log-rank 
(Mantel-Cox) test. (19B) - Representative photographs of Conrol, Danusertib and YM155 treated 
mice after 4-week treatment course. The blue arrows indicate the livers of control and treated 
groups. The liver of control group displays hepatomegaly with macroscopic tumor lesions. (19C) - 
Percentage of Alu+ positive human cells relative to the total cell number in mouse livers and lungs 
of control and drug treated groups after 4-week treatment course. 
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4.3. Survivin: A therapeutic target for metastatic pancreatic cancer. 
4.3.1. Assessment of Survivin protein expression in PDX metastatic models.   
Since the treatment with the Survivin suppressor (YM155) exerted the best anti-metastatic activity, 
we focused on its further characterization. First, the protein expression of Survivin was assessed in 
Panc265 metastatic model used in scRNA sequencing experiment. Interestingly, IHC analysis 
revealed nuclear expression of Survivin protein in primary tumor cells, CTCs, liver and lung 
metastatic cells (Figure 20A,B). Most of the tumor cells positive for Survivin are undergoing 
mitosis, mostly in metaphase and anaphase (histological observation). Moreover, 
immunofluorescence (IF) nicely confirmed its nuclear localization in CTCs isolated from the 
highly metastatic Panc265 model (Figure 20B). The protein expression of Survivin was also 
evaluated in the other metastatic models and the IHC showed nuclear expression of the protein in 
the primary and metastatic lesions of all PDX models, thus suggesting that Survivin may play an 
essential role in tumor cell division during the metastasis progression of pancreatic cancer.  
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Figure 20. Evaluation of Survivin protein expression in metastatic PDX models of pancreatic 
cancer. (20A) – Representative images of immunohistochemistry (IHC) staining for Survivin in 
tumor, liver and lung tissues of metastatic PDX models (scale bar 50µm). (20B) – Top panel - 
Representative images of IHC staining for Survivin in human pancreatic CTCs isolated from 
highly metastatic PDX model (scale bar 50µm and 10µm). Bottom panel - Representative 
Immunoflourescence image of human Survivin (green) and Dapi (blue) in human pancreatic CTCs 
(scale bar 25µm). 
 
4.3.2. Early In-vivo efficacy study with YM155 and Abraxane in a highly metastatic Panc265 
model. 
Panc265 metastatic model exhibits the most aggressive phenotype with the shortest survival rate 
and early dissemination. This led us to test whether earlier initiation of YM155 theatment could 
result in improvement of median survival compared to previous study. Mice harboring a highly 
metastatic Panc265 orthotopic model were divided into four experimental groups: (1) Control; (2) 
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YM155; (3) ABX; (4) YM155+ABX. Two days after tumor implantation the groups were 
subjected to 4-week treatment course. After cessation of the treatment, the median survival of the 
groups was evaluated and the results showed that YM155 monotherapy significantly prolonged the 
median survival to 56 days in comparison to control group. (Figure 21A, Table13). ABX 
monotherapy show no statistically significant improvement in median survival compared with 
YM155 treatment (Figure21A, Table13). Remarkable, the median survival of the animals in 
YM155 + ABX combination was statistically superior to that of ABX and YM155 alone 
(Figure21A, Table13), suggesting possible synergistic interaction between ABX and YM155. 
In addition, one mouse treated with ABX and two mouse treated with YM155+ABX combo 
achieved a complete response (eradication of primary tumor) with no detectable metastasis. At the 
survival endpoint, the tumor-bearing mice of all treated groups displayed the usual signs of 
sickness (described in methods) caused by the progression of metastatic disease. 
 
The metastatic tumor burden of YM155 treated mice sacrificed at the same time point as the 
control animals, was also examined. Strikingly, earlier initiation of the YM155 treatment totally 
blocked the tumor dissemination with no detectable macro and micrometastasis in liver and lung 
organs compared with control group (Figure21B, Table 14). Moreover, the weight of the tumor 
grafts of YM155 treated group was significantly smaller than that of the control group (Figure 
21C). 
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Figure 21. Early In-vivo efficacy study of YM155 and ABX in a highly metastatic Panc265 
model.  
(21A) - Treatment course in PDX mice harbouring a highly metastatic Panc265 model (top). 
Kaplan–Meir survival curves of control and drug treated groups. (Table13) - The table shows the 
median survival days and statistical significance of the experimental groups. Survival data were 
analyzed using GraphPad Prism 6 software. P-values for survival differences were calculated using 
the log-rank (Mantel-Cox) test. (21B) -Representative photographs of Control and YM155 treated 
mice and their corresponding liver and lung organs after 4-week treatment course. The blue arrows 
indicate the livers of control and treated groups. The liver of control group displays hepatomegaly 
with macroscopic tumor lesions, whereas the liver of YM155 groups has normal size. (Table 14) - 
Summary table of metastatic incidence in control and YM155 treated groups (21C) - Weights of 
the tumors including the mouse pancreas resected from control and YM155 treated group. Bar 
represents that the weight of the tumors including the mouse pancreas of YM155 group is smaller 
than of control group. * Tumor including the mouse pancreas. **P < 0.001 versus control group.  
 
4.3.3. Primary tumor resection of a highly metastatic Panc265 model in combination with 
YM155 and Abraxane therapy.  
To mimic the clinical therapeutic setting for pancreatic cancer, we performed resection of primary 
tumor combined with YM155 and Abraxane combo treatment in a highly metastatic Panc265 
model. In this study we established the following three experimental groups (1) Control; (2) 
YM155; (3) YM155+ABX. One week after implantation the YM155 treatment course was 
initiated and 11 days post-implantation all mice underwent partial pancreatectomy that was 
performed by an electrocautery system. The treatment course was reinitiated 3 days after the 
surgery including the Abraxane regimen (Figure 22A,B) 
 
Interestingly, the median survival of the control mice subjected to partial pancreatectomy was 35 
days. During the necropsy, it was observed macroscopic local tumor invasion to the adjacent 
organs such as peritoneum and remaining lobes of the pancreas, as well as distal overt metastasis 
to the liver and lung organs, thus representing equal metastatic pattern to that of Panc265 
orthotopic model (Figure22C). Remarkable, after cessation of the treatment course YM155 and 
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YM155+ABX treatment resulted in extending the median survival to 60 and 67 days respectively 
and it was statistically significant in comparison to control group (Figure 22D, Table 15). 
However, the combo regimen was unable to statistically improve the median survival compared to 
monotherapy treatment (Figure 22D, Table 15). At the survival endpoint, the tumor-bearing mice 
of all groups displayed the usual signs of sickness (described in methods) caused by the 
progression of metastatic disease. 
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Figure 22. In-vivo efficacy study of YM155 and ABX in a highly metastatic Panc265 model 
subjected to partial pancreatectomy.  
(22A) – Treatment course in PDX mice implanted with a highly metastatic Panc265 model and 
subjected to partial pancreatectomy for removal of primary tumor graft. (22B) - Representative 
photographs of the pancreatectomy procedure using a bipolar electrocautery. The top picture 
shows mice under anestesia and the heated electrode is applied to the exposed pancreas implanted 
with Panc265 xenograft model. The bottom picture shows a representative photographs of the 
resected pancreas and spleen. (22C) – Representative photographs of control group mice sacrificed 
upon reaching a human endpoint criteria. The white arrow shows the macroscopic metastatic 
nodules in the liver. (22D) – Kaplan–Meir survival curves of control and drug treated groups. 
(Table 15) - The table shows the median survival days and statistical significance of the 
experimental groups. Survival data were analyzed using GraphPad Prism 6 software. P-values for 
survival differences were calculated using the log-rank (Mantel-Cox) test. 
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4.2.4. In-vivo efficacy study with YM155 and Abraxane in Panc198 metastatic model.  
Next, we tested whether YM155 treatment could have similar anti-metastatic activity in other 
metastatic PDX models. For this reason, we established four experimental groups using Panc198 
metastatic models: (1) Control; (2) YM155; (3) ABX; (4) YM155+ABX. Two weeks after tumor 
implantation the experimental groups were subjected to 4-week treatment course. The results 
showed that YM155 monotherapy significantly prolonged the median survival to 62 days in 
comparison to control group (54.5 days) (Figure 23A, Table16). ABX monotherapy showed a 
significant advantage compared to YM155 alone by prolonging the survival to 68 days (Figure 
23A, Table16). Interestingly, the combination of YM155+ABX showed a median survival of 77 
days and it was superior to YM155 and ABX single agents (Figure 23A, Table16). At the survival 
endpoint, the tumor-bearing mice of all groups displayed the usual signs of sickness (described in 
methods) caused by the progression of primary tumor and/or metastatic disease. 
 
To evaluate wheter YM155 treatment exerted any effect on metastatic tumor burden, we sacrificed 
small set of animals from YM155 treated group at the same time point as the control group. 
Interestengly, microscopic examination of the distant organs confirmed the presence of several big 
metastatic nodules in livers and lungs of the control mice (Figure 23B). In contrast, the YM155 
treated mice had much fewer and smaller metastatic lesions in liver and lung parenchyma. 
Altogether this data suggests that the survival benefit of YM155 treatment could be due to the 
reduction of metastatic tumor burden. However, further studies are needed to precicely explain the 
beneficial effects of this drug in metastatic PDX models of pancreatic cancer.  
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Figure 23. In-vivo efficacy study of YM155 and Abraxane in Panc198 metastatic model. 
(23A) – Treatment course in PDX mice harbouring a metastatic Panc198 model (top). Kaplan–
Meir survival curves of control and drug treated groups. (Table 16) - The table shows the median 
survival days and statistical significance of the experimental groups. Survival data were analyzed 
using GraphPad Prism 6 software. P-values for survival differences were calculated using the log-
rank (Mantel-Cox) test. (23B) - Representative photographs of control and YM155 treated mice 
implanted with Panc198 model (top). The white arrow shows the macroscopic metastatic nodules 
in the control liver. Representative photomicrographs of liver and lung tissues resected from 
control and YM155 treated mice (bottom). The metastatic lesions composed of human tumor cells 
are detected by Alu staining and indicated by red circles. (scale bar 1000-5000µm). 
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4.4. The role of tumor-derived exosomes in organotropic metastasis. 
4.4.1. Isolation and proteomics analysis of tumor-derived exosomes from Metastatic PDX 
models. 
 
The metastatic models established in this thesis are characterized by specific dissemination pattern. 
Two of these models have a propensity to metastasize to the liver and lung organs, whereas the 
other five models disseminate only to the lungs. We wondered whether this metastasis 
organotropism could be determined by molecules present on tumor-derived exosomes. To test this 
hypothesis, we profiled the exosomal proteome of five metastatic models (Panc265, Panc198, 
Panc020, Panc042, Panc047). After reaching the humane end point criteria, the orthotopic tumor-
bearing animals from each model were sacrificed and in collaboration with Hector Peinado´s 
group we purified the exosomes of primary tumor and metastatic organs (liver and/or lung) 
(Figure24A,B).  
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Figure 24. Exosomes release from metastatic PDX models. (A) Left vertical panels represents 
the number of exosomes particles purified from the primary tumors of metastatic PDX models, 
total protein extracted from the isolated exosomes and the exosome concentration presented as μg 
exosomal protein per exosome particle (up to down, respectively). Right vertical panels represents 
the number of exosomes particles purified from liver and lung organs, total protein extracted from 
the isolated exosomes and the exosome concentration presented as μg exosomal protein per 
exosome particle (up to down, respectively). 
 
 
Next, the protein extract of the exosomes was subjected to further proteomics analysis. The label 
free mass spectrometry of primary tumor, liver and lung exosomes identified 5456 proteins of 
which 1901 were human specific and 3555 were murine (Figure 25). Then, we compared the 
exosome proteome of metastatic models that colonize to the liver and lung (hereafter, they are 
abbreviated as “Aggressive”) versus the metastatic models that metastasize primarily to the lung 
(hereafter, they are abbreviated as “Less-Aggressive”). The main goal of this comparison was to 
establish proteome signatures that can cluster the models based on their aggressiveness and/or their 
metastatic pattern. This comparison identified 181 differentially abundant human proteins between 
aggressive and less-aggressive primary tumor exosomes, and 11 human proteins between 
aggressive and less-aggressive lung exosomes. However, the unsupervised hierarchical clustering 
of these differentially abundant human proteins derived from the primary tumors and metastatic 
sites failed to separate the aggressive from less-aggressive models (Figure 26-27).  
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Figure 25. Unsupervised hierarchical clustering of exosomal secretome profiles. Hierarchical 
clustering of exosomal secretome profiles (n = 5456 human/mouse proteins with ≥1 peptides) of 
primary tumor grafts and metastatic organs collected from metastatic PDX models. Three 
biological replicates with two technical replicates of each metastatic model are included and each 
of the secretomes are shown. The entire protein list was used. Columns represent samples; rows 
are proteins. Relative protein abundance is colored-coded with red corresponding to a relatively 
high abundance, black corresponding to a relatively low abundance. 
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Figure 26. Significantly abundant exosomal proteins in primary tumor grafts of metastatic 
PDX models. Volcano plot show the log2 fold change above 1.5 (p value 0.05, FDR 0.01) in 
exosomal proteins of primary tumor grafts (aggressive vs less-aggressive models) Welch t-test 
analysis was performed on proteins (1716 proteins) present in 70% of the samples of at least one 
of the 2 groups. Bottom-left - Hierarchical clustering of 181 differentially abundant human 
exosomal proteins showed a separation of the aggressive models from most of less-aggressive 
models (except Panc20). Bottom-right - Hierarchical clustering of 63 differentially abundant 
mouse exosomal proteins. 
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Figure 27. Significantly abundant proteins in lungs of metastatic PDX models. Volcano 
plots show the log 2 fold change above 1.5 (p value 0.05, FDR 0.01) in exosomal proteins of 
lung tissues (aggressive vs less-aggressive models) Welch t-test analysis was performed on 
proteins (1836 proteins) present in 70% of the samples of at least one of the 2 groups. Bottom-left 
- Hierarchical clustering of 11 differentially abundant human proteins showed a separation of the 
aggressive models from most of less-aggressive models (except Panc20). Bottom-right - 
Hierarchical clustering of 27 differentially abundant mouse proteins. 
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4.4.2. Identification of organ-specific exosomal protein signatures. 
To establish the “organ-specific” exosomal protein signatures, we compared the exosomal protein 
profiles of all organs to each other. 634 significantly abundant human proteins were identified 
between primary tumor- and liver-derived exosomes, 648 human proteins between primary tumor- 
and lung-derived exosomes and 21 proteins between liver- and lung-derived exosomes. 
Remarkable, the unsupervised hierarchical clustering nicely separated the three biological groups 
(primary tumor, liver and lung of each PDX model) from each other, based on their distinct 
exosomal protein signatures (Figure 28-30).  
 
Next, we interrogated these differentially abundant protein signatures with aim to identify potential 
candidate proteins associated with the metastatic disease and organotropic metastasis. 
Interestingly, we identified that the human protein ITGa6 was abundantly expressed in primary 
tumor exosomes and it was identified by at least 1 peptide in at least 70% of the lung-derived 
exosomes (Figure 31, Table S4). S100A11 is another protein that was identified to be abundantly 
expressed in primary tumor- and lung-tropic exosomes compared to liver-derived proteome profile 
(Figure 31, Table S4). These two protein candidates have been found to be abundantly expressed 
in the exosomes of multiple cancer types including pancreatic cancer, which suggest that they may 
have a role in metastatic disease. However, additional studies are needed to elucidate their 
contribution to organotropic metastasis in pancreatic cancer.  
 
Moreover, Vimentin is another protein that was present in at least 70% of the lung-derived 
exosomes and it was abundantly expressed in primary tumor exosomes (Figure 31, Table S4). 
However, despite the overwhelming amount of literature describing the role of Vimentin in 
essential steps of metastatic cascade such as EMT process during tumor invasion (see chapter 
1.2.3), the precise role of this intermediate filament protein in organotropic metastasis have not 
been officially documented.  
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Figure 28. Significantly abundant proteins in Livers vs PDAC of metastatic PDX models. 
Volcano plots show the log 2 fold change above 1.5 (p value 0.05, FDR 0.01) in exosomal 
proteins in PDAC vs Livers. Welch t-test analysis was performed on proteins (1964 proteins) 
present in 70% of the samples of at least one of the 2 groups. Bottom-left - Hierarchical clustering 
of 634 differentially abundant human proteins showed a separation of the primary tumour profiles 
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from liver profiles. Bottom-right - Hierarchical clustering of 668 differentially abundant mouse 
proteins. 
       
 
Figure 29. Significantly abundant proteins in Lung vs PDAC of metastatic PDX models. 
Volcano plots show the log 2 fold change above 1.5 (p value 0.05, FDR 0.01) in exosomal 
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proteins in PDAC vs Livers. Welch t-test analysis was performed on proteins (2403 proteins) 
present in 70% of the samples of at least one of the 2 groups. Bottom-left - Hierarchical clustering 
of 648 differentially abundant human proteins showed a separation of the primary tumour profiles 
from lung profiles. Bottom-right - Hierarchical clustering of 885 differentially abundant mouse 
proteins. 
 
Figure 30. Significantly abundant proteins in Lung vs Liver of metastatic PDX models. 
Volcano plots show the log 2 fold change above 1.5 (p value 0.05, FDR 0.01) in exosomal 
proteins in Lungs vs Livers. Welch t-test analysis was performed on proteins (1925 proteins) 
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present in 70% of the samples of at least one of the 2 groups. Bottom-left - Hierarchical clustering 
of 19 differentially abundant human proteins showed a separation of the primary tumour proteome 
profiles from liver proteome profiles. Bottom-right - Hierarchical clustering of 1042 differentially 
abundant mouse proteins. 
 
 
Figure 31. Human proteins present in at least 70% of lung-tropic exosome samples. 
Hierarchical clustering of the human proteins present in at least 70% of the lung-tropic exosome 
samples (n = 37 human proteins with ≥1 unique peptide). Columns represent samples; rows are 
proteins. Relative protein abundance is colored-coded with red corresponding to a relatively high 
abundance, black corresponding to a relatively low abundance. 
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V. DISCUSSION.  
 
5.1. Metastatic PDX models of pancreatic cancer. 
5.1.1. PDX orthotopic models of pancreatic cancer: An efficient and reproducible In-vivo 
system for modeling the metastatic disease.  
 
Unfortunately, the vast majority of the pancreatic cancer patients are diagnosed in late stage with 
presence of distal metastasis. This short window between diagnosis and disease progression for 
advanced pancreatic cancer extremely limits the study of metastatic disease in clinical settings. 
Over the past decades, animal models have been commonly used as an In-vivo tool for modelling 
the metastatic process of multiple cancer types. For successful modelling pancreatic cancer 
metastasis, several In-vivo models have been used including injection of murine or human cancer 
cell lines directly in mouse circulation, development of GEMM of pancreatic cancer and 
establishment of PDX models by orthotopic transplantation of intact human pancreatic specimens 
in nude immunodeficient mice. However, the main drawbacks of these models are: 1) direct 
injection of cancer cells in mouse circulation bypasses some initial steps of metastasis such as 
invasion and intravasation, and therefore cannot perpetuate the entire process; 2) The GEMM of 
pancreatic cancer generally exhibit long tumor and metastatic latency, as well as the metastatic 
incidence in these models remains relatively low; 3) The orthotopic transplantation of patient 
pancreatic tumors in nude mice results in low metastatic rate [90-91]. Altogether, this leads to an 
urgent demand for development of more efficient metastatic pancreatic models.  
 
For this reason, one of the first goals of this thesis was to improve the current available 
experimental metastasis models by development of an efficient, fast and reproducible In-vivo 
platform, which accurately recapitulates the entire multi-step metastatic process of pancreatic 
cancer. Indeed, the seven metastatic PDX models generated in this study were able to established 
distal metastasis with a high reproducibility rate. Moreover, each model is characterized with 
different survival rate and model-specific dissemination pattern. Contrary to the metastatic PDX 
models of pancreatic cancer described in the literature, the models in this thesis were generated in 
a highly immunodeficient mouse background (NSG mice), which allowed this high metastatic 
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incidence. This observation is in agreement with other study showing that reduction of host 
immunity correlates with higher metastatic rate [143].  
 
However, as discussed above, the critical aspect for development of these metastatic PDX models 
is the need to use immunodeficient mouse recipients for successful tumor engraftment and 
subsequent colonization to distant organs. It has been widely reported the tumour-promoting and 
tumour-suppressing roles of the immune system in cancer progression and metastasis. Therefore, 
next generation “personalized immune” mouse models will be needed to observe the impact of the 
autologous immune elements on cancer spreading. Of major interest, currently, is the development 
of preclinical models with reconstituted immune system from the donor patient. These so-called 
“humanized” mouse models with immune system reconstituted upon transplantation of 
hematopoietic stem cells aspirated from bone marrow of an individual cancer patient, may provide 
a new In-vivo system to study the molecular mechanisms mediating the anti-metastatic immune 
responses, as well as to test new immunomodulatory agents with aim to enhance the anti-tumour 
immune response. 
 
5.1.2. Metastatic PDX models: a source for efficient enrichment of all human tumor 
populations involved in metastatic disease. 
 
Cancer metastasis is a dynamic multi-step process, composed of distinct tumor cell populations. 
To understand the metastatic disease at cellular and molecular level, first it is important to develop 
an appropriate platform for enrichment and purification of the tumor populations involved in 
metastatic process. In clinical practice, the most common method for isolation of viable tumor 
cells of epithelial origin is based on using antibodies specific to epithelial membrane markers such 
as EpCAM among others. For example, CellSearch
® 
is the only FDA-approved method for 
enumeration of CTCs of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+) 
in whole blood. However, as discussed in chapter 2.2.3, the epithelial tumor cells need to undergo 
phenotypic changes to complete the entire metastatic cascade. Some of these changes are 
accompanied by loss of epithelial markers expression and acquisition of mesenchymal-associated 
genes, process known as EMT. In addition, we also observed that the primary tumors and 
metastatic lesions in 6 out of 7 metastatic PDX models contain cells positive for the classical 
Spas Dimitrov Markov 
87 
 
mesenchymal marker vimentin, suggesting that these cells may be undergoing EMT ( see chapter 
2.2.1). Therefore, the use of epithelial-marker-based enrichment approaches may lead to selective 
loss of some tumor populations.  
 
For this reason the next goal of this thesis was to develop a method, that enables the identification 
of all human tumor populations involved in metastatic process. Taken into account the interspecies 
difference between the tumor and host cells in the PDX models, we searched for a ubiquitously 
expressed epithelial-independent human specific surface marker to discriminate the human tumor 
cells from host mouse cells. Among others, the HLA-ABC was a good candidate for enrichment of 
the human tumor cells, since it is robustly expressed on the surface of all nucleated cells. Indeed, 
flow cytometry analysis showed that the HLA marker was also abundantly expressed in tumor 
cells from two of the metastatic PDX models and therefore this allowed us to develop a highly 
sensitive, species-specific magnetic separation method, and enriched all human tumor populations 
from the mouse peripheral tissues (primary tumor, blood and metastatic organs) with negligible 
false-positive rate. HLA-ABC was also superior to the commonly used epithelial marker EpCAM 
(data no shown, lab observation). Unfortunately, this species-specific, epithelial-marker-
independent method cannot be used for isolation of tumor cells including CTCs from patients 
samples, because all cells are of human origin. Therefore, future research is needed to identify new 
selection markers that are robustly expressed in pancreatic tumor cells and not subjected to 
phenotypic changes. 
 
5.1.3. Pancreatic CTC populations contain tumor- and metastasis-initiating cells.  
 
CTCs are a key intermediate event in metastatic process, which is indispensible for generation of 
the future metastatic lesions. It has been hypothesized that CTC populations in the blood of 
patients with carcinoma may contain cells with the clonal capacity to initiate metastatic growth in 
distant organs, thus behaving as MICs. Indeed, the presence of CTC in patient blood has been 
associated with metastatic disease and decreased overall survival in several types of carcinoma 
[144]. To date, only two studies were able to demonstrate that the CTCs populations isolated from 
breast and lung cancer patients possess tumorigenic and metastatic capacity upon transplantation 
in immunodeficient mice [139-140]. Although these findings support the hypothesis that CTC 
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populations contain MICs, the existence and functional characterization of circulating MICs in the 
context of pancreatic cancer have not been formally documented [145].  
A major barrier to identify these circulating metastatic cells is that they might be present at very 
low number in blood of the pancreatic patients. In this regard, a recent study reported that the 
median CTCs number in the peripheral blood of PDAC patients is 3 CTCs/7.5 ml [146]. This low 
number of pancreatic CTCs might extremely limit their molecular and functional characterization. 
In fact, over the last 2 years our laboratory has been trying to generate PDX models from the blood 
of metastatic PDAC patients using “negative enrichment” approach with anti-CD45 antibody for 
depletion of the white blood cells. The CD45- fractions obtained from PDAC patients were unable 
to produce tumors in immunodeficient mice. The method for development of these desirable 
patient CTC-derived xenograft models is under continues improvement process, but up to date no 
patient CTC-derived xenograft model of pancreatic cancer has been generated.  
 
To overcome this issue, we exploited the metastatic PDX models as an efficient In-vivo platform 
to produce sufficient number of human pancreatic CTCs for further molecular and functional 
studies. In truth, the positive HLA-ABC fraction isolated from a highly metastatic Panc265 model 
was 6x10
4 
cells/10 ml mouse blood and it was more than sufficient to investigate the In-vivo 
tumorigenic and metastatic capacity of these tumor cells. In vivo transplantation of human 
pancreatic CTCs in immunodeficient mice resulted in generation of human tumors in 7 out of 8 
transplants and lung metastasis in all recipient animals, thus demonstrating that the human 
pancreatic CTC population is enriched of functional TICs and MICs. Moreover, the CTC-derived 
tumors retained the principal morphological characteristics of the parental tumor. Orthotopic 
implantation of fragments established from CTCs-derived tumors in small set of animals resulted 
in similar survival rate to that of the parental tumor and sporadic macro and micro metastasis in 
distant organs (data no shown, lab observation). Altogether, this data suggests that the CTCs 
population may also contain tumor cells with stem cell features capable of regenerating the entire 
parental tumor. In conclusion, we successfully demonstrated the existence of TICs and MICs 
within the pancreatic CTCs population isolated from a highly metastatic PDX model. However, 
future functional studies will be necessary to confirm their tumorigenic and metastatic capacity in 
the other metastatic models. Further phenotypic characterization of these rare, life-threatening cells 
Spas Dimitrov Markov 
89 
 
to identify pancreatic MIC-specific markers and their subsequent validation in prospective clinical 
studies, is also of crucial importance.  
5.2. Single-cell dissection of the transcriptional heterogeneity during the metastatic 
progression of pancreatic cancer. 
 
Cancer metastasis is a highly heterogeneous disease, composed of multiple cell populations 
distinct from one another, which are subjected to a continuously evolving process. This Intra-
tumoral heterogeneity results from mutations, transcriptional changes and clonal selection 
dynamics during tumor growth, where individual tumor cells accumulate cell-specific genetic 
changes. This clonal heterogeneity is significantly associated with tumor progression and 
metastasis.  
 The recently developed single-cell sequencing technologies provide the highest-resolution 
analysis of intra-tumoral heterogeneity. In contrast to the conventional bulk-sequencing methods, 
these single-cell analysis are able to uncover the heterogeneous behaviors of rare tumor 
populations and therefore facilitate the identification of specific genetic alterations or gene 
expression signatures involved in the tumor progression and metastasis. Indeed, a recent study 
exploited the scRNA sequencing technology to decipher the transcriptional heterogeneity of breast 
cancer metastasis in mouse xenograft models [147]. The single-cell sequencing in this study 
revealed that low-burden metastatic lesions are composed of cells with stem-cell- ,EMT-, pro-
survival- and dormancy-associated gene expression properties, whereas high-burden metastatic 
lesions contain cancer cells with similar gene expression signature with that of the primary tumor. 
However, despite these considerable advances in metastasis research, the transcriptional 
heterogeneity of metastatic disease in pancreatic cancer still remains poorly studied. 
  
In this thesis, we exploited the metastatic PDX models of pancreatic cancer and the single-cell 
technology to answer the question whether the tumor populations (primary tumor, CTCs, liver 
metastatic cells) involved in tumor progression are transcriptionally distinct from one another. The 
single-cell analysis revealed considerable transcriptional heterogeneity between the three 
biological groups and the PCA plot demonstrated that the intra-population heterogeneity is more 
pronounced in CTC group, showing more dispersed pattern than the other two groups. Altogether 
these findings suggest that the metastatic disease of pancreatic cancer is a well-organized 
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evolutionary process, where cell subpopulations derived from the primary tumor are continuously 
modifying their transcriptomic program until they complete the entire metastatic cascade.  
5.2.1 ECM interaction and focal adhesion, cell cycle and ribosome biogenesis signatures are 
the major aspects of the transcriptional intra-tumor heterogeneity during pancreatic cancer 
metastasis.  
The characterization of the aspects (gene sets and biological pathways), which reflect the 
transcriptional intra-tumoral heterogeneity in the context of cancer is also needed for gaining more 
knowledge in cancer progression and metastasis. Using a recently developed bioinformatics 
method (PAGODA) for resolving the transcriptional diversity at single-cell level, we successfully 
characterize the previously uncovered transcriptional heterogeneity between the tumor populations 
involved in metastatic process. This bioinformatic analysis identified that three main biological 
patherns: ECM interaction and focal adhesion, Cell Cycle and Ribosome biogenesis define this 
intra-tumoral heterogeneity.  
 
In contrast to the primary tumor cells, ECM interaction signature mainly composed of collagen 
genes is significantly down-regulated in CTCs and liver metastatic cells. The differential 
expression of these ECM-related genes could reflect the adaptation of the metastatic cells to the 
new tissue environment, where the stromal compartment and ECM composition are different from 
those in primary tumor niche. In fact, this result is coherent with findings of previous studies, 
which reported a significant variation in the expression of human extracellular matrix-related 
genes that were significantly down-regulated in xenografts compared with patients tumors [148]. 
  
The cell cycle is the second biological pattern, which was found to be repressed in CTC 
population. Moreover, in contrast to primary tumor and metastatic cells, the majority of the CTCs 
reside in G1 phase, thus suggesting that they might be in a state of dormancy. Indeed, many 
hypotheses have been proposed to explain this single-cell dormancy model. According to this 
model, individual cancer cell or cell clusters detach from primary tumor mass and arrive at the 
secondary homing sites, where they enter in a prolong dormant state by which they retard or 
suspend their replication completely until conditions favor their re-entry into the next-cell cycle. In 
this regard, recent studies supported this hypotheses by demonstrating that CTCs and metastatic 
cells from low-burden tissues isolated from pancreatic and breast cancer mouse models show low-
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proliferative signature compared with their respective primary tumor and metastatic cells from 
high-burden tissues [106;147]. Altogether, these findings support that the pancreatic CTCs in this 
metastatic PDX model may remain dormant or slow-cycling with prolonged interphase until they 
establish overt metastasis at distant organs. However, additional studies are needed to confirm 
whether the CTCs exist in an inactive or active cycling state.  
 
Interestingly, the third major aspect of the transcriptional heterogeneity is driven by a gene set 
associated with ribosome biogenesis, which is up-regulated in CTC population. It is well known 
that cell growth and proliferation are associated with changes in the rate of ribosome biogenesis. In 
fact, it was reported that the rRNA synthesis is increased during G1 phase and ribosome assembly 
is required for the protein synthesis during S phase. On other hand, downregulation of ribosome 
activity might be required during mitotic (M) phase for proper exit from the cell cycle. This was 
confirmed by other studies showing that the synthesis of rRNA reaches maximal levels in S phase 
and G2 phases, it is decreased in M phase and it is increased in G1 phase [149-151]. In agreement 
with these observations, the high expression levels of ribosome-associated genes in pancreatic 
CTC population might be tightly linked to their cell-cycle state. Indeed, in contrast to the primary 
tumor and metastatic population, which contain a large proportion of cells in G2/M phase, the 
majority of CTCs reside in G1 phase, therefore suggesting that they may remain in dormant or 
slow-cycling mode with prolonged interphase in which, as mentioned above, the rRNA synthesis 
is increased.  
 
5.2.2. Single-cell RNA sequencing: a reliable method for identification of anti-metastatic 
targets.  
The ultimate goal of studying the cancer metastasis is to develop effective anti-metastatic 
therapeutic strategies that will prolong the patient’s survival. A large body of evidence suggests 
that metastasis is regulated by the expression of multiple genes necessary for completion of each 
step in the metastatic cascade and transcriptional regulation of metastasis-related genes is one 
possible mechanism to promote metastasis. This notion has encouraged many researchers to rely 
on gene-expression studies to pinpoint molecular mechanisms involved in metastatic process. 
Indeed, over the last few years, many studies discovered important metastasis-associated genes in 
different cancer types by exploring the gene-expression profiles of tumour populations, which 
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participate in metastatic process. For example, scRNA sequencing has been applied to decipher the 
transcriptional programs of the CTCs, where several metastasis-promoting genes have been 
identified to be up-regulated in CTCs population, and their knockdown in cancer cells suppress 
cell migration and invasiveness [105, 106].   
 
Encouraged by these observations, we also considered that scRNA sequencing would be an 
appropriate approach to find relevant metastasis-associated genes, which can be further use for 
design of new and more effective therapeutic strategies against pancreatic cancer metastasis. 
Indeed, the detailed analysis of transcriptional program of the human pancreatic CTCs revealed 
numerous up-regulated genes and pathways such as BIRC5 (Survivin), AURKA, AURKB, PLK1, 
IL32 among others and the majority of them have been previously described in the literature to 
play important roles in cancer progression and metastasis. Moreover, pharmacological targeting of 
some of these genes (BIRC5, AURKA and AURKB) in our metastatic PDX models resulted in 
significant increase in survival of the treated animals and significant reduction in metastatic tumor 
burden. Altogether, these results are in agreement with the previous findings confirming that the 
scRNA-seq profiling of cancer cells with key roles in metastatic process might be a powerful and 
reliable tool for discovery of relevant metastasis-related genes, which in turns could contribute to 
improvement of the therapeutic strategies against metastatic disease.  
 
5.2.3. Survivin: A therapeutic target for metastatic pancreatic cancer.  
 
Survivin has been discovered to be one of the components of the chromosomal passenger complex 
(CPC) regulating chromomal segregation and cytokinesis during mitosis [152]. Loss of function of 
Survivin or of one of its partners (AURKB, INCENP and DASRA B) upon RNAi-mediated 
inhibition resulted in disturbed segregation of chromosomes and defective cytokinesis [153-157]. 
Furthermore, Survivin knock-out in yeasts and C. elegans confirmed the role of Survivin in 
mitosis. In vertebrates, the essential role of Survivin during mitosis has been confirmed in Xenopus 
laevis and mice [158-159]. On the other hand, besides its functions in mitosis Survivin is 
associated with multiple roles in apoptotic regulation [160-162]. However, within the N-terminus 
of Survivin, there is only one baculoviral inhibitor of apoptosis repeat (BIR) domain. Also 
Survivin contains no C-terminal RING finger domain which is common for members of the IAP 
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family [163-164]. Therefore, although overexpression of Survivin might act as an anti-apoptotic 
factor, it appears conceivable that the Survivin-knockout phenotypes which were interpreted as 
loss of anti-apoptotic function might be primarily linked to deregulated mitotic processes. 
 
In the context of cancer disease, Survivin has been found to promote tumor progression by 
regulating cell division and apoptosis [165-166]. It has been also reported that its overexpression 
enhances tumor invasion and metastasis in several cancer types [167-168]. Moreover, it has been 
recently reported that Survivin is highly expressed in CTCs isolated from prostrate cancer patients 
[169], as well as another recent study demonstrated that the expression levels of detergent soluble 
cytoplasmic Survivin in colorectal cancer cell lines correlated inversely with anoikis susceptibility 
in colorectal cancer [170]. However despite these advances, the precise role of Survivin in 
pancreatic cancer progression and metastasis remains poorly understood.  
 
In this thesis work, we first identified that the mRNA expression level of Survivin was 
significantly higher in the human pancreatic CTCs compared to that in primary tumor cells. 
Second, Survivin was also expressed at protein level in the CTCs, primary tumor and metastatic 
cells derived from a highly metastatic Panc265 model. The protein expression of Survivin was 
assessed in the other metastatic models, showing the presence of Survivin-positive cells in primary 
tumor and metastatic sites of all metastatic models. The protein expression pattern of Survivin in 
all models was nuclear, thus suggesting that its function might be linked to cell division. Third, the 
pharmacological targeting of Survivin by using a small-molecule inhibitor YM155 (currently in 
clinical trials) resulted in significant improvement in survival of treated mice implanted with two 
of our metastatic models(Panc265 and Panc198), prolonged survival of the animals that were 
subjected to partial pancreatectomy for removal of primary tumor graft, and significant reduction 
in metastatic tumor burden. Altogether, this data give reasons to think that Survivin might play a 
role in tumor cell division during the metastasis progression of pancreatic cancer.  
 
Despite these convincing results, however, additional studies are necessary to better elucidate the 
precise role of Survivin in pancreatic cancer metastasis. This includes the following: 1) Evaluation 
of Survivin protein expression in CTCs derived from the other metastatic PDX models; 2) Knock-
down of Survivin in pancreatic metastasis-competent cancer cell lines by using shRNAs in order to 
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determine whether suppression of Survivin expression would impair their metastatic properties 
after tail-vein injection in immunodeficient mice; 3) Assessment of Survivin protein expression in 
pancreatic tumor patient specimens with aim to determine whether high expression of Survivin 
correlates with poor prognosis in PDAC patients. Moreover, the median survival of YM155 
(survivin inhibitor) monotherapy was similar to that of Abraxane monotherapy, as well as the 
combo treatment with Abraxane resulted in a significant increase in median survival compared to 
the monotherapy regimens. Therefore, these data provide the rational for further investigation of 
anti-tumoral and anti-metastatic activity of this combo therapy in pancreatic cancer. 
 
5.3. The role of tumor-derived exosomes in organotropic metastasis. 
One salient feature of cancer metastasis is that some cancer cells preferentially metastasize to 
specific organs, under the control of multiple cellular and molecular mechanisms. Many studies 
focused largely on pinpointing intrinsic cancer cell properties which determine this organotropic 
metastasis, including genes, chemokine receptors expressed on cancer cells or tumor-secreted 
systemic factors. In recent years, tumor-derived exosomes have been demonstrated to promote 
cancer progression. In fact, recent studies have reported that the tumor exosomes which express 
specific integrins can determine the organotropic metastasis in various cancer types by preparing 
the pre-metastatic niche via their integrins-mediated fusion with organ-specific resident cells [80].  
Based on these recent research findings, we also hypothesized that the tumor-derived exosomes 
may have a role in determining the metastatic organotropism observed in metastatic PDX models 
of pancreatic cancer. In collaboration with Hector Peinado`s group and Proteomics unit from 
CNIO, we were able to isolate and purify exosomes from different tissues and quantitative MS was 
able to identify proteins of human origin extracted from the exosomes derived from primary tumor 
and metastatic sites. Moreover, the unsupervised hierarchical clustering of the significantly 
abundant human proteins resulted in clear distinction between primary tumors, liver and lung 
proteome profiles. However, this type of analysis was unable to completely separate the exosomal 
protein signature of the aggressive models from that of less-agressive models. This could be due to 
the small number of differentially abundant human proteins identified in the liver and lung organs, 
as well as the small number of metastatic models used in this study( in total five PDX models – 2 
aggressive and 3 less-agressive).  
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Next, we interrogated these “organ-specific” exosome protein signatures to search for potential 
protein candidates that might be associated with the metastatic disease and organotropic 
metastasis. Interestingly, the proteomics analysis identified that ITGa6, S100A11 and Vimentin 
proteins are abundantly expressed in primary tumor- and lung-tropic exosomes, but not in the 
exosomes from the liver organs. ITGa6 is a member of transmembrane proteins, whose function is 
associated with cell adhesion, proliferation, cell differentiation and cell migration [171]. In fact, 
recent study identified enrichment of several integrin proteins including ITGa6 in human exosomes 
derived from multiple organotropic tumor models [80]. Notably, ITGa6 was abundantly expressed 
in the exosomes of breast, osteosarcoma, rhabdomyosacoma, Wilms’tumor and melanoma cell 
lines, which have propensity to metastasize to the lung, as well as in the exosomes derived from 
uveal melanoma, pancreatic and gastric cancer cells that colonize primarily to the liver. On the 
other hand, S100A11 is a member of the S100 calcium binding family and it has been associated 
with lymph node metastasis in metastatic non-small cell lung cancer, metastatic hepatocellular 
carcinoma and pancreatic adenocarcinoma [172-173]. Recently, S100A11 together with other 
S100 proteins was identified in mesothelioma cell-derived exosomes [174]. Vimentin is a type III 
intermediate filament protein, which has been reported to regulate a number of key cancer 
biological functions including EMT, cell migration and invasion, cell-cell and cell-substrate 
adhesion among others. However, despite the important role of this cytoskeletal protein in 
numerous processes implicated in metastatic disease, to the best of our knowledge, its precise role 
in organotropic metastasis has not been formally reported. Collectively, this data provides a 
scientific rationale for further investigating the role of these three exosomal proteins in pancreatic 
cancer spreading and metastatic organotropism. 
 
In summary, the PDX metastatic models of pancreatic cancer developed in this thesis work 
provide an efficient, faithful and reproducible In-vivo system for modeling of the entire metastatic 
process. This In-vivo platform allowed the identification and isolation of all tumor populations 
involved in metastatic process, which in turns facilitated the transcriptional dissection of the 
metastatic disease at single-cell level, as well as the discovery of novel therapeutic targets for 
pancreatic cancer metastasis. Also, the use of these metastatic PDX models facilitated the 
molecular characterization of the tumor-secreted exosomes, which helped to better understand 
their role in organotropic metastasis.  
Spas Dimitrov Markov 
96 
 
VI. CONCLUSIONS  
 
1. The metastatic PDX models of pancreatic cancer developed in this thesis provide an 
efficient and reproducible In-vivo platform for accurate modeling of the entire multi-step 
metastatic process and for isolation of all tumor populations involved in metastatic disease.  
 
2. The human pancreatic circulating tumor cells (CTCs) possess high tumorigenic and 
metastatic capacity. The CTC-derived tumors preserve the morphological characteristics of 
parental tumor.  
 
3. The metastatic disease of pancreatic cancer is a well-organized evolutionary process, where 
the primary tumor cells, metastatic cells and CTCs are transcriptionally distinct from one 
another. The transcriptional heterogeneity between these three biological groups is defined 
by three biological patterns which are ECM interaction and focal adhesion, Cell cycle and 
ribosome biogenesis.  
 
4. The single-cell transcriptome dissection of metastatic disease was able to uncover 
numerous deregulated metastasis-associated genes. Survivin is one of these metastasis-
related genes which is up-regulated in CTCs and the pharmacological targeting of this gene 
was able to reduce the metastatic tumor burden and improve the median survival of the 
metastatic PDX models of pancreatic cancer. Additionally, protein expression of Survivin 
was detected in primary tumors and metastatic sites of all metastatic PDX models, which 
suggests that Survivin can be a prognostic marker and anti-metastatic therapeutic target for 
pancreatic cancer metastasis.  
 
5. Although the protein profiling of the exosomes purified from primary tumors and 
metastatic sites of metastatic PDX models failed to separate the “aggressive” from “less-
aggressive” models, this proteomic analysis identified an “organ-specific” exosomal 
protein signatures with abundant expression of several metastasis-associated exosome 
proteins. 
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ANNEXE I – Supplementary material 
 
 
 Table S1. TNM staging classification for exocrine pancreatic cancer. This table demostrates the 
anatomic stage of the disease and the prognostic groups. 
 
 
 
Definition  
  
Primary tumor(T) 
Tx                              Primary tumor cannot be evaluated. 
T0                              No evidence of primary tumor. 
Tis                             Carcinoma in situ, including “PanIII“ classification. 
T1                              Tumor limited to the pancreas ≤ 2 cm in greatest diameter 
T2                              Tumor limited to the pancreas > 2 cm in greatest diameter 
T3                              Tumor extends beyond the pancreas without involvement of the  
                                   celiac axis or superior mesenteric artery. 
T4                   Tumor involves the celiac axis or the superior mesenteric artery 
(unresectable primary tumor).  
Regional Lymph Nodes (N) 
NX                               Regional lymph nodes cannot be evaluated 
N0                                No regional node metastasis 
N1                                Regional lymph node metastasis 
 
 
Distal Metastasis (M) 
MX                              Distant metastasis cannot be evaluated. 
M0                               No distant metastasis 
M1                               Distant metastasis 
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Stage grouping 
Stage 0                     Tis           N0               M0                             
Stage IA                   T1           N0               M0               
Stage IB                   T2           N0               M0                  
Stage IIA                 T3           N0               M0                
Stage IIB                  T1          N1               M0              
                                  T2          N1              M0                 
                                  T3          N1              M0                 
Stage III                   T4          Any N         M0 
Stage IV                   Any T    Any N         M1  
 
 
 
 
 
Table S2. This table summarizes the statistically significant deregulated genes identified by 
scRNA-seq in CTCs versus primary tumor cells. 
Symbol log2 fold change direction FDR 
FOS -10.2 down-regulated 8.5008E-09 
TGFBI -11.4 down-regulated 8.5008E-09 
COL1A2 -9.2 down-regulated 1.0596E-05 
EGR1 -11.0 down-regulated 1.1231E-05 
SAT1 -3.5 down-regulated 4.3182E-05 
KLF6 -3.0 down-regulated 0.00011433 
IL32 4.2 up-regulated 0.00014097 
SCD -10.2 down-regulated 0.00058038 
COL1A1 -10.1 down-regulated 0.00102859 
CD44 -2.1 down-regulated 0.00230985 
MAN2A1 -7.3 down-regulated 0.00411704 
SLC39A11 -9.5 down-regulated 0.00411704 
HSP90B1 -2.0 down-regulated 0.00429505 
ITGB8 -3.2 down-regulated 0.00429505 
TSC22D1 -8.2 down-regulated 0.00429505 
TAPBP -2.6 down-regulated 0.00507435 
PTTG1 2.5 up-regulated 0.00519431 
CD109 -8.5 down-regulated 0.00547216 
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Table S3. This table summarizes the differentially deregulated genes identified by scRNA-seq in 
CTCs versus liver metastatic tumor cells. 
GLRX 2.6 up-regulated 0.00547216 
MARCKS -2.7 down-regulated 0.00659957 
TNS3 -7.4 down-regulated 0.00659957 
COL6A3 -3.8 down-regulated 0.00750599 
DNMT3A -7.2 down-regulated 0.00750599 
CCNB1 3.1 up-regulated 0.00842524 
FOSB -6.9 down-regulated 0.00842524 
IGFBP3 -8.5 down-regulated 0.00842524 
STEAP3 -6.9 down-regulated 0.00895967 
DHRS3 -7.8 down-regulated 0.00925168 
AMIGO2 -6.9 down-regulated 0.01023283 
LIPA -7.0 down-regulated 0.01160081 
CDKN3 3.0 up-regulated 0.01176546 
SLC5A3 -9.3 down-regulated 0.01291935 
KIAA1109 -6.7 down-regulated 0.01304171 
THBS1 -6.9 down-regulated 0.01304171 
ZFP36 -3.1 down-regulated 0.01411937 
SPARC -2.8 down-regulated 0.01693196 
PCMTD1 -7.3 down-regulated 0.01854657 
COL11A1 -6.8 down-regulated 0.01930312 
COL3A1 -6.6 down-regulated 0.02172881 
NFKBIZ -6.8 down-regulated 0.02351611 
NR4A2 -6.5 down-regulated 0.02416221 
BIRC5 3.2 up-regulated 0.02880758 
BAG2 2.4 up-regulated 0.0302595 
ELP2 -6.6 down-regulated 0.03576705 
CTSC -2.3 down-regulated 0.04264083 
CALU -3.1 down-regulated 0.04532532 
SRPX -7.7 down-regulated 0.04532532 
Symbol log2 fold change direction FDR 
KLF6 -2,6 down-regulated 0,045742 
SPARC -3,2 down-regulated 0,096095 
EIF5 2,4 up-regulated 0,129277 
CD44 -1,7 down-regulated 0,188729 
TNS3 -7,2 down-regulated 0,188729 
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EGR1 -10,1 down-regulated 0,19307 
CAPZA1 1,4 up-regulated 0,253283 
LIPA -6,6 down-regulated 0,253283 
SLC1A5 -6,3 down-regulated 0,263756 
EYA3 2,1 up-regulated 0,295456 
KIAA1109 -6,1 down-regulated 0,360318 
EPDR1 -5,9 down-regulated 0,367628 
EXT2 -5,9 down-regulated 0,367628 
HSPA5 -3,3 down-regulated 0,367628 
PPP1CB 1,4 up-regulated 0,367628 
PPP6R3 1,9 up-regulated 0,367628 
YWHAE 1,6 up-regulated 0,367628 
CDC42 1,4 up-regulated 0,423215 
COL1A2 -5,6 down-regulated 0,423215 
CTSC -2,1 down-regulated 0,423215 
MAN2A1 -5,7 down-regulated 0,423215 
OS9 -5,9 down-regulated 0,423215 
RPN2 -2,2 down-regulated 0,423215 
SAR1A 1,4 up-regulated 0,423215 
DNMT3A -5,6 down-regulated 0,486752 
HSP90B1 -1,5 down-regulated 0,486752 
NR4A2 -5,4 down-regulated 0,486752 
SRPX -7,0 down-regulated 0,486752 
ZFP36 -2,9 down-regulated 0,486752 
FOS -8,1 down-regulated 0,51287 
GLRX 1,9 up-regulated 0,51287 
TAPBP -2,0 down-regulated 0,51287 
TGFBR1 -5,7 down-regulated 0,536809 
ARL8B 2,1 up-regulated 0,537001 
CTSB -2,0 down-regulated 0,537001 
DYNC2H1 -6,7 down-regulated 0,537001 
GLT25D2 -5,4 down-regulated 0,537001 
IL32 2,2 up-regulated 0,537001 
LEPRE1 -5,2 down-regulated 0,537001 
PIGU -5,4 down-regulated 0,537001 
TNFAIP2 -5,3 down-regulated 0,537001 
ZBTB11 -5,4 down-regulated 0,537001 
ZW10 -6,1 down-regulated 0,537001 
MAP1A -5,2 down-regulated 0,547961 
STEAP3 -5,3 down-regulated 0,547961 
ABCC1 -6,3 down-regulated 0,565401 
ARHGEF10 -4,4 down-regulated 0,565401 
ARHGEF9 -4,6 down-regulated 0,565401 
ARPC4 1,4 up-regulated 0,565401 
ARRB1 -4,6 down-regulated 0,565401 
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ATL2 -4,8 down-regulated 0,565401 
BAG2 1,6 up-regulated 0,565401 
BRD3 -4,9 down-regulated 0,565401 
CALU -2,4 down-regulated 0,565401 
CCDC93 2,7 up-regulated 0,565401 
CCL2 -4,8 down-regulated 0,565401 
CHIC1 -4,8 down-regulated 0,565401 
COL11A1 -4,5 down-regulated 0,565401 
COL1A1 -5,7 down-regulated 0,565401 
DHRS1 -4,9 down-regulated 0,565401 
DHX38 -4,9 down-regulated 0,565401 
DRAP1 1,8 up-regulated 0,565401 
DUSP1 -7,1 down-regulated 0,565401 
EIF5A 1,7 up-regulated 0,565401 
ELP2 -5,2 down-regulated 0,565401 
EMR1 -5,4 down-regulated 0,565401 
ESYT1 -6,3 down-regulated 0,565401 
FAM204A 1,6 up-regulated 0,565401 
FAS -6,5 down-regulated 0,565401 
FASTKD5 -4,7 down-regulated 0,565401 
G6PC3 -5,1 down-regulated 0,565401 
GALNT14 -5,0 down-regulated 0,565401 
GFPT2 -4,5 down-regulated 0,565401 
GIPC2 0,1 up-regulated 0,565401 
GLMN -5,2 down-regulated 0,565401 
HIST1H2BD -5,0 down-regulated 0,565401 
HIST1H4C -1,7 down-regulated 0,565401 
ILVBL -4,7 down-regulated 0,565401 
ITPR2 -5,0 down-regulated 0,565401 
LOC729013 -4,9 down-regulated 0,565401 
MAGEH1 -4,3 down-regulated 0,565401 
MPDU1 -5,1 down-regulated 0,565401 
MRS2 -5,0 down-regulated 0,565401 
MTRNR2L8 -2,8 down-regulated 0,565401 
NEK11 -4,7 down-regulated 0,565401 
NUCB1 -4,8 down-regulated 0,565401 
P4HA2 -7,7 down-regulated 0,565401 
PEX11B -4,9 down-regulated 0,565401 
PIGL -4,7 down-regulated 0,565401 
QKI 1,7 up-regulated 0,565401 
RCE1 -5,0 down-regulated 0,565401 
RGMB -4,7 down-regulated 0,565401 
RPN1 -1,7 down-regulated 0,565401 
SERPINA3 -4,5 down-regulated 0,565401 
SERPINE1 -2,0 down-regulated 0,565401 
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SERPINI1 -5,0 down-regulated 0,565401 
SIL1 -5,4 down-regulated 0,565401 
SLC35C2 -4,7 down-regulated 0,565401 
SLC4A2 -4,7 down-regulated 0,565401 
SNORA61 -4,9 down-regulated 0,565401 
TBL2 -5,0 down-regulated 0,565401 
TGFBI -8,5 down-regulated 0,565401 
TMBIM6 -1,7 down-regulated 0,565401 
TMEM109 -4,9 down-regulated 0,565401 
TMEM205 -6,3 down-regulated 0,565401 
TMEM25 -4,9 down-regulated 0,565401 
TSPAN3 -6,2 down-regulated 0,565401 
UNC5C -4,7 down-regulated 0,565401 
WDR19 -4,7 down-regulated 0,565401 
ZAK 1,8 up-regulated 0,565401 
ZFAND2A -5,1 down-regulated 0,565401 
ZFP90 -4,7 down-regulated 0,565401 
ZNF184 -4,9 down-regulated 0,565401 
GPATCH2 -4,5 down-regulated 0,565542 
SESN1 -4,5 down-regulated 0,567814 
DGKH -4,3 down-regulated 0,572791 
HIST1H2BG -4,4 down-regulated 0,572791 
ZCCHC14 -4,8 down-regulated 0,572791 
MTRNR2L2 -2,6 down-regulated 0,581013 
RGS2 -4,4 down-regulated 0,587162 
ASAP2 1,9 up-regulated 0,587522 
MYO9A -5,0 down-regulated 0,587522 
PGRMC1 -5,9 down-regulated 0,587522 
SLC2A12 -4,6 down-regulated 0,587522 
TTL 2,2 up-regulated 0,587522 
YES1 2,0 up-regulated 0,587522 
FUT11 -4,4 down-regulated 0,590232 
TOR1B -4,5 down-regulated 0,590232 
ZNF473 -4,3 down-regulated 0,590232 
SAP30BP 1,5 up-regulated 0,599247 
AACS -4,3 down-regulated 0,608199 
ADAMTS3 -4,2 down-regulated 0,608199 
AGL -5,8 down-regulated 0,608199 
ALYREF 2,2 up-regulated 0,608199 
APH1B -4,4 down-regulated 0,608199 
BBS12 -4,3 down-regulated 0,608199 
CCDC15 -4,2 down-regulated 0,608199 
CCDC150 -4,1 down-regulated 0,608199 
CETN3 1,7 up-regulated 0,608199 
CHST14 -4,0 down-regulated 0,608199 
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CNPY4 -4,2 down-regulated 0,608199 
CSPG4 -4,7 down-regulated 0,608199 
CSRNP1 -4,1 down-regulated 0,608199 
CYB561 -5,2 down-regulated 0,608199 
DSC2 -4,4 down-regulated 0,608199 
ELMOD2 -4,9 down-regulated 0,608199 
FAM57A -4,6 down-regulated 0,608199 
FBXL4 -4,2 down-regulated 0,608199 
FOSB -4,4 down-regulated 0,608199 
FSTL1 -4,1 down-regulated 0,608199 
GPR107 -4,2 down-regulated 0,608199 
HDDC3 -4,2 down-regulated 0,608199 
HIVEP3 -4,4 down-regulated 0,608199 
HYOU1 -6,8 down-regulated 0,608199 
JUNB -4,6 down-regulated 0,608199 
LINC00461 -4,2 down-regulated 0,608199 
LRRC6 -4,4 down-regulated 0,608199 
NDST2 -4,2 down-regulated 0,608199 
NRM -6,2 down-regulated 0,608199 
NUCKS1 1,8 up-regulated 0,608199 
NUDT12 -4,2 down-regulated 0,608199 
PPT2 -4,0 down-regulated 0,608199 
PROCR -6,9 down-regulated 0,608199 
RALGAPA2 -4,2 down-regulated 0,608199 
RBFA 2,0 up-regulated 0,608199 
RRNAD1 -4,2 down-regulated 0,608199 
SCFD2 -4,7 down-regulated 0,608199 
SET 1,2 up-regulated 0,608199 
SNF8 1,7 up-regulated 0,608199 
SP110 -4,2 down-regulated 0,608199 
TESK2 -4,3 down-regulated 0,608199 
TIAM2 -4,1 down-regulated 0,608199 
TM9SF4 -6,0 down-regulated 0,608199 
TMEM87B -4,3 down-regulated 0,608199 
UBE2J1 2,8 up-regulated 0,608199 
UXS1 -5,6 down-regulated 0,608199 
ZFP91 1,9 up-regulated 0,608199 
KDELR3 -6,1 down-regulated 0,615725 
LOX -5,6 down-regulated 0,615725 
PCMTD1 -5,8 down-regulated 0,61794 
TTC13 -4,1 down-regulated 0,626415 
ADCY7 -4,5 down-regulated 0,627955 
AGBL2 -3,7 down-regulated 0,627955 
B9D1 -4,7 down-regulated 0,627955 
BCAP31 -1,8 down-regulated 0,627955 
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Table S4. This table summarizes the statistically significant deregulated genes identified by 
scRNA-seq in liver metastatic cells versus primary tumor cells. 
 
Symbol log2 fold change direction FDR 
ADAM19 -2.5 down-regulated 2.8403E-09 
ARRDC3 -3.3 down-regulated 2.8403E-09 
MARCKS -2.5 down-regulated 2.8403E-09 
PPP1CB -1.6 down-regulated 2.8403E-09 
TGFBI -2.9 down-regulated 2.8403E-09 
TIMP3 -5.2 down-regulated 2.8403E-09 
SAR1A -1.4 down-regulated 5.205E-09 
DMD -4.9 down-regulated 1.2617E-08 
PCDH10 3.8 up-regulated 9.119E-08 
AMIGO2 -6.6 down-regulated 3.0982E-07 
CBX3 1,3 up-regulated 0,627955 
FYCO1 -4,0 down-regulated 0,627955 
GPX3 -3,9 down-regulated 0,627955 
HARBI1 -4,3 down-regulated 0,627955 
MTBP -4,0 down-regulated 0,627955 
PDSS1 -4,1 down-regulated 0,627955 
SFT2D2 -3,8 down-regulated 0,627955 
BHLHE40 -7,9 down-regulated 0,629459 
CXCL2 -4,5 down-regulated 0,629459 
ELL3 -3,7 down-regulated 0,629459 
EMC10 -3,7 down-regulated 0,629459 
GSTM4 -3,8 down-regulated 0,629459 
HIST1H3H -3,9 down-regulated 0,629459 
KLHDC2 -3,9 down-regulated 0,629459 
PLOD1 -1,9 down-regulated 0,629459 
PRMT6 -4,2 down-regulated 0,629459 
SNHG5 1,3 up-regulated 0,629459 
TBCCD1 2,2 up-regulated 0,629459 
VPS26A 1,5 up-regulated 0,629459 
ACYP2 -3,3 down-regulated 0,629574 
APCDD1L -3,7 down-regulated 0,629574 
ATAT1 -3,9 down-regulated 0,629574 
BBS2 -4,1 down-regulated 0,629574 
BIRC5 1,3 up-regulated 0,629574 
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EGLN3 -4.7 down-regulated 3.0982E-07 
FKBP9 -2.1 down-regulated 7.4802E-07 
OGT -2.1 down-regulated 8.8619E-07 
HTR7 -4.2 down-regulated 1.086E-06 
SCG2 -4.7 down-regulated 1.6584E-06 
HNRNPH1 -1.5 down-regulated 2.1047E-06 
NNMT -4.1 down-regulated 3.1587E-06 
FAP -6.1 down-regulated 1.085E-05 
HAS2 -5.1 down-regulated 1.9916E-05 
EIF2S3 -1.2 down-regulated 3.1781E-05 
SCD -2.6 down-regulated 3.1781E-05 
MAP1B -1.2 down-regulated 4.5832E-05 
YWHAE -1.2 down-regulated 6.3675E-05 
TMEM255B -4.4 down-regulated 7.9097E-05 
SLC5A3 -3.0 down-regulated 9.2085E-05 
PTPRS -3.3 down-regulated 0.00011948 
SLC38A2 -1.8 down-regulated 0.00011948 
CCNB1 2.8 up-regulated 0.0001224 
WSB1 -1.9 down-regulated 0.00014495 
EDEM1 -1.8 down-regulated 0.00015393 
MFAP5 -5.2 down-regulated 0.00015393 
EMP1 -1.9 down-regulated 0.00016158 
SERINC5 -1.6 down-regulated 0.00016801 
NBPF7 -2.4 down-regulated 0.00021388 
TUBB4B 1.9 up-regulated 0.00024854 
CTTN -1.0 down-regulated 0.0005519 
GNAT2 -3.6 down-regulated 0.00071133 
TRA2A -1.4 down-regulated 0.00071133 
ITGB1 -0.9 down-regulated 0.00081994 
LUC7L3 -1.4 down-regulated 0.00081994 
DHRS3 -3.7 down-regulated 0.00087735 
AKR1B1 6.4 up-regulated 0.00095662 
PTTG1 1.9 up-regulated 0.00095662 
NCOA3 -2.2 down-regulated 0.0009694 
CDC20 2.9 up-regulated 0.00097208 
ISG20 -4.4 down-regulated 0.00101281 
ITGB8 -3.0 down-regulated 0.00101281 
NDRG1 -5.0 down-regulated 0.00106938 
EML4 -1.9 down-regulated 0.00115579 
PHLDA1 -1.6 down-regulated 0.00126871 
H2AFZ 1.1 up-regulated 0.00131256 
MMP2 -6.0 down-regulated 0.00131256 
MEDAG -2.1 down-regulated 0.0013541 
ANKRD10 -2.3 down-regulated 0.00152615 
LPCAT2 -2.3 down-regulated 0.00155481 
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SLC39A11 -1.5 down-regulated 0.00158768 
THBS1 -3.1 down-regulated 0.00158768 
TRPS1 -1.8 down-regulated 0.00158768 
ZNF624 -3.8 down-regulated 0.00158768 
ZNF860 -4.2 down-regulated 0.00158768 
CDK5R1 -3.8 down-regulated 0.00165957 
SNORA21 -2.3 down-regulated 0.00193537 
PIP4K2A -1.3 down-regulated 0.0019448 
GOLGB1 -1.5 down-regulated 0.00214186 
STRN3 -1.5 down-regulated 0.00214186 
FOSB -2.4 down-regulated 0.00238158 
DDAH1 -1.3 down-regulated 0.00240829 
POC1A 2.9 up-regulated 0.00243587 
REEP3 -1.2 down-regulated 0.00251206 
TTC3 -1.7 down-regulated 0.00268344 
BDH2 -3.9 down-regulated 0.00292976 
TMEM41B -1.5 down-regulated 0.00300527 
PTP4A2 -1.1 down-regulated 0.00335196 
MALAT1 -1.5 down-regulated 0.00341394 
B4GALT1 -1.1 down-regulated 0.00346242 
LOC284454 -2.3 down-regulated 0.00346242 
VMP1 -1.2 down-regulated 0.00357634 
RGCC -3.0 down-regulated 0.00387567 
CDH11 -5.4 down-regulated 0.00402644 
CXCL5 3.7 up-regulated 0.00499098 
CTNNB1 -1.2 down-regulated 0.00529025 
QKI -1.2 down-regulated 0.00529025 
STAT2 -1.5 down-regulated 0.00529025 
USP34 -1.4 down-regulated 0.00529025 
FLRT2 -0.5 down-regulated 0.00543632 
R3HDM2 -1.4 down-regulated 0.00561332 
SAT1 -1.8 down-regulated 0.00561923 
HMOX2 1.6 up-regulated 0.00599731 
IGF1R -1.8 down-regulated 0.0061133 
C10orf54 -3.3 down-regulated 0.00641251 
LTBP1 -5.4 down-regulated 0.00684805 
POP5 1.6 up-regulated 0.00684805 
MKI67 2.8 up-regulated 0.00687913 
PSRC1 4.4 up-regulated 0.00747682 
RUVBL2 1.7 up-regulated 0.00775024 
GPRC5A -4.7 down-regulated 0.00788746 
BCAT1 -1.1 down-regulated 0.0081639 
COL6A3 -1.4 down-regulated 0.00846345 
EIF4B -1.2 down-regulated 0.00846345 
KPNA2 1.8 up-regulated 0.0088105 
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MRPS12 1.2 up-regulated 0.00913211 
NTSR1 -3.8 down-regulated 0.00913211 
AKAP12 -1.2 down-regulated 0.0094233 
LOXL1 -5.1 down-regulated 0.00948594 
PDGFA -3.9 down-regulated 0.00986067 
TSC22D1 -2.7 down-regulated 0.01036084 
PDGFC -1.7 down-regulated 0.01046011 
CALD1 -4.1 down-regulated 0.01048367 
TIMP1 -1.4 down-regulated 0.0105297 
TMEM154 -4.0 down-regulated 0.01066111 
NOG -4.0 down-regulated 0.0107623 
CA12 -4.4 down-regulated 0.01084554 
ARL4C -1.6 down-regulated 0.01097926 
CD109 -1.6 down-regulated 0.01141628 
SYNE1 -2.1 down-regulated 0.01162825 
CNIH3 -4.2 down-regulated 0.01215826 
RAP2C -1.2 down-regulated 0.01215826 
RIN2 -1.4 down-regulated 0.01215826 
PTHLH -2.6 down-regulated 0.01252327 
KIF4A 2.3 up-regulated 0.01314675 
RBPJ -1.8 down-regulated 0.01314675 
USP18 4.2 up-regulated 0.01314675 
FOS -2.1 down-regulated 0.0132021 
PLOD2 -1.9 down-regulated 0.01327152 
KLF12 -4.5 down-regulated 0.01354669 
LPP -1.4 down-regulated 0.01356365 
ARPC4 -1.1 down-regulated 0.01408836 
HAS2-AS1 -0.7 down-regulated 0.01408836 
UBR1 -2.1 down-regulated 0.01408836 
SYT1 -2.1 down-regulated 0.01427144 
ARF6 -1.2 down-regulated 0.01526575 
FBN1 -2.6 down-regulated 0.01624549 
SLC2A1 -2.2 down-regulated 0.01669102 
CDC42 -0.8 down-regulated 0.0170762 
PMEPA1 -1.9 down-regulated 0.0170762 
PON3 -2.8 down-regulated 0.0170762 
TLK1 -1.1 down-regulated 0.0170762 
H3F3B 0.7 up-regulated 0.01709381 
ZC3HC1 2.6 up-regulated 0.01722442 
CDCA3 2.5 up-regulated 0.01744472 
EDEM3 -1.7 down-regulated 0.01744472 
SKIL -1.5 down-regulated 0.01836637 
SLC20A1 -1.3 down-regulated 0.01845839 
ATRX -1.2 down-regulated 0.0193895 
PAQR7 -1.6 down-regulated 0.01947123 
Spas Dimitrov Markov 
122 
 
PJA2 -1.4 down-regulated 0.01947123 
RNF144A -2.3 down-regulated 0.01947123 
SERINC1 -1.2 down-regulated 0.01947123 
TSPYL1 -0.9 down-regulated 0.01947123 
CAPZA1 -0.7 down-regulated 0.01959184 
PRR5L -4.4 down-regulated 0.02004494 
SEMA3C -1.7 down-regulated 0.02004494 
NFKBIZ -3.3 down-regulated 0.0200719 
CDCA8 2.5 up-regulated 0.02008844 
IQGAP1 -1.0 down-regulated 0.02072443 
ARHGAP1 -1.4 down-regulated 0.02073285 
MIR4714 -1.9 down-regulated 0.02076434 
TOB1 -1.4 down-regulated 0.02116123 
MATN3 -3.7 down-regulated 0.02126894 
MLL3 -2.0 down-regulated 0.02126894 
FAM3C -1.3 down-regulated 0.02161174 
ITGB5 -2.0 down-regulated 0.02184877 
AURKB 2.5 up-regulated 0.02193636 
ITPR3 -5.3 down-regulated 0.02193636 
TUBA1C 1.0 up-regulated 0.02193636 
MIER1 -1.1 down-regulated 0.02211827 
TUBB 0.8 up-regulated 0.02222688 
PSMC4 0.7 up-regulated 0.02370362 
THAP5 -1.2 down-regulated 0.02370362 
PSMB5 0.9 up-regulated 0.0245046 
TPX2 2.0 up-regulated 0.0245046 
FNIP1 -1.4 down-regulated 0.02462276 
GPR183 -0.4 down-regulated 0.02515702 
SNTB2 -1.3 down-regulated 0.02515702 
TUFM 1.4 up-regulated 0.02515702 
ENTPD5 -4.0 down-regulated 0.02553252 
COL3A1 -2.3 down-regulated 0.0258858 
PPL -4.8 down-regulated 0.0258858 
RNF26 2.4 up-regulated 0.0258858 
HSF2BP 4.1 up-regulated 0.02720888 
TUBA1A -0.9 down-regulated 0.02748426 
SEC22B -0.9 down-regulated 0.02826093 
NDC80 2.1 up-regulated 0.02827151 
CCDC164 -2.0 down-regulated 0.0303265 
COG1 -3.3 down-regulated 0.0303265 
COPS6 1.2 up-regulated 0.0303265 
TMPO 1.5 up-regulated 0.0303265 
UBE2D3 1.1 up-regulated 0.0303265 
CDCA5 1.9 up-regulated 0.03041914 
TGFBR2 -2.0 down-regulated 0.03041914 
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DST -0.9 down-regulated 0.03065429 
DLGAP5 2.1 up-regulated 0.03076129 
BUB3 0.9 up-regulated 0.03093549 
MAD2L1 2.1 up-regulated 0.03144197 
MYADM -1.2 down-regulated 0.03155583 
FAM32A 1.6 up-regulated 0.03250276 
KCTD18 -3.0 down-regulated 0.03431073 
TUBA1B 0.8 up-regulated 0.03490438 
GADD45A 2.9 up-regulated 0.03639458 
GLS -1.4 down-regulated 0.03803619 
CABYR 3.0 up-regulated 0.0393121 
ITPRIPL2 -1.2 down-regulated 0.03934289 
YWHAZ -0.6 down-regulated 0.03934289 
HN1 1.1 up-regulated 0.03938609 
PDCD4 -1.2 down-regulated 0.0401303 
SRSF6 -1.2 down-regulated 0.0410698 
GOLGA3 -1.2 down-regulated 0.04138667 
TRPM7 -1.4 down-regulated 0.04139845 
N4BP2L2 -1.5 down-regulated 0.04173372 
C12orf23 -1.3 down-regulated 0.04215506 
CCNB2 2.4 up-regulated 0.04215506 
DEPDC1 2.3 up-regulated 0.04215506 
MGA -1.6 down-regulated 0.04215506 
SLC30A1 -3.5 down-regulated 0.04215506 
TAF1D -1.4 down-regulated 0.04215506 
AHI1 -1.4 down-regulated 0.04239187 
EFNA5 -1.4 down-regulated 0.04239201 
PPP6R3 -1.0 down-regulated 0.04293361 
AGBL2 3.3 up-regulated 0.04361627 
HMGB2 1.6 up-regulated 0.04361627 
KIF5A -3.2 down-regulated 0.04394212 
GLIPR1 -2.5 down-regulated 0.04429346 
WIPF1 -4.6 down-regulated 0.04698874 
RFX2 -0.5 down-regulated 0.04716232 
ADAM20 -0.5 down-regulated 0.04811704 
ANKRD40 -0.9 down-regulated 0.04811704 
TOP2A 2.4 up-regulated 0.049078 
CEP55 1.8 up-regulated 0.04922169 
ELOF1 2.3 up-regulated 0.04922169 
PRKD1 -5.0 down-regulated 0.04922169 
SYNGR2 3.1 up-regulated 0.04922169 
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Table S5. This table summarizes the 37 human proteins present in at least 70% of lung-tropic 
exosome samples. 
Gene 
names 
Organism 
Welch's 
T-test q-
value 
liver vs 
pdac 
Welch's 
T-test 
Differenc
e liver_vs 
pdac 
Welch's T-
test q-
value  
 lung vs 
pdac 
Welch's T-
test 
Difference 
lung vs 
pdac 
Welch's 
T-test q-
value  
Lung vs 
Liver 
Agress 
Welch's 
T-test 
Differenc
e Lung vs 
Liver 
Agress 
MUC5AC Human 0,000 -8,619 0,000 -9,481 0,582034 -1,34754 
FLG2 Human 0,052 0,783 0,651 0,504 0,942197 -0,16826 
SBSN Human 1,000 0,000 0,016 -0,904 0,412 -0,73624 
SPHK2 Human 1,000 0,000 0,000 3,143 0,000 2,517859 
OSBP Human 0,471 -0,230 0,667 -0,140 0,605753 0,271438 
HMGA2 Both (H) 0,000 -1,986 0,000 -1,400 0,385279 0,548807 
AHNAK Human 0,000 -4,242 0,000 1,890 0,000 6,051396 
ITGA6 Both (H) 0,000 -3,582 0,000 -3,196 0,811296 0,270408 
SELENBP1 Human 1,000 0,000 0,000 4,961 0,003055 2,995849 
CAT Human 0,992 0,030 0,010 1,241 0,810952 0,738166 
GYG2 Human 1,000 0,000 0,000 4,222 0,000 4,236656 
VIM Human 0,000 -5,175 0,000 -4,475 0,263803 0,787262 
FLNA Both (H) 0,000 -5,294 0,000 -7,476 0,000229 -2,83524 
FASN Human 0,000 -11,249 0,000 -11,441 0,978201 -0,04014 
PKM Human 0,000 -7,812 0,000 -5,603 0,023483 1,999727 
GAPDH Human 0,000 -6,791 0,000 -3,978 0,001096 2,959638 
PYGB Human 0,000 -6,410 0,000 -2,635 0,000 3,659831 
TUBB8 Human 0,000 -5,416 0,295 -0,664 0,000 4,052232 
HSP90AA1 Human 0,000 -7,234 0,000 -6,746 0,969518 -0,05596 
HSP90AB2P Human 0,015 0,530 0,307 -0,274 0,000 -0,72257 
EEF1G Human 0,000 -6,334 0,000 -6,076 0,920133 -0,14221 
COPA Human 0,000 -1,950 0,000 -1,080 0,008813 1,118923 
FARSA Human 0,000 -3,804 0,000 -1,643 0,000164 2,091284 
S100A11 Both (H) 0,000 -4,794 0,727 0,256 0,000 4,79905 
ALDH1A1 Human 0,002 2,520 0,000 3,550 0,710454 0,222613 
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MVP Human 0,000 -8,378 0,000 -9,633 0,009234 -1,81275 
PFN1 Human 0,000 -7,630 0,000 -7,446 0,772751 -0,75945 
PLEC Human 0,000 -8,778 0,000 -8,704 0,737791 -0,2451 
ENO1 Human 0,000 -6,217 0,000 -5,080 0,281622 0,670389 
PGK1 Both (H) 0,000 -7,713 0,000 -6,203 0,888656 0,415717 
PFKP Human 0,000 -7,510 0,000 -7,888 0,860276 -0,37297 
HSPB1 Human 0,000 -8,726 0,000 -8,023 0,037227 0,859078 
ESD Human 0,000 -8,853 0,000 -7,679 0,000662 1,55881 
UBA1 Both (H) 0,000 -8,959 0,000 -8,381 0,066775 0,837086 
WDR1 Human 0,000 -2,719 0,000 -2,818 0,135165 -0,21826 
CLIC1 Human 0,000 -7,899 0,000 -6,231 0,071362 1,386115 
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ANNEXE II – Conference presentations 
 
Abstract B42: Patient-derived metastatic models of pancreatic cancer: An in-vivo system for 
modeling metastasis and preclinical drug screening. 
Spas Dimitrov, Manuel Muñoz, Natalia Baños, Camino Menéndez, Victoria Bonilla, Yolanda Dur
an, Rodrigo Toledo, Francesca Sarno, Javier Perales-Patón, Fátima Al-Shahrour, Pedro P. Lopez-
Casas and Manuel Hidalgo 
DOI: 10.1158/1557-3265.PDX16-B42 Published August 2016. 
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VI. CONCLUSIONES 
1. Los modelos metastásicos PDX de cáncer de páncreas desarrollados en esta tesis 
proporcionan una plataforma in-vivo eficiente y reproducible para modelar de forma 
precisa  todo el proceso metastásico y para el aislamiento de todas las poblaciones 
tumorales implicadas en la enfermedad metastásica. 
2. Las células tumorales circulantes (CTC) pancreáticas humanas poseen alta capacidad 
tumorigénica y metastásica. Los tumores derivados de CTC preservan las características 
morfológicas del tumor parental. 
3. La enfermedad metastásica del cáncer de páncreas es un proceso evolutivo bien 
organizado, donde las células tumorales primarias, las células metastásicas y los CTC son 
transcripcionalmente distintos entre sí. La heterogeneidad transcripcional entre estos tres 
grupos biológicos se define por tres patrones biológicos que son la interacción ECM y la 
adhesión focal, el ciclo celular y la biogénesis ribosómica. 
4. La disección de transcriptoma al nivel individual de la enfermedad metastásica fue capaz 
de descubrir numerosos genes desregulados asociados con la metástasis. Survivina es uno 
de estos genes relacionados con la metástasis que está sobreexpresado en CTC y el bloqueo 
farmacológico de este gen fue capaz de reducir la carga tumoral metastásica y mejorar la 
supervivencia media de los modelos metastáticos PDX de cáncer de páncreas. Además, la 
expresión de la proteína survivina se detectó en los tumores primarios y sitios metastásicos 
de todos los modelos metastásicos PDX, lo que sugiere que survivina puede ser un 
marcador pronóstico y una diana terapéutica anti-metastásica para la metástasis del cáncer 
pancreático. 
5. Aunque el perfil proteico de los exosomas purificados de los tumores primarios y sitios 
metastásicos de los modelos metastásicos PDX no logró separar los modelos "agresivos" 
de "menos agresivos", este análisis proteómico identificó firmas proteómicas "órgano-
específicas" con abundante expresión de varias proteínas exosomales asociadas con la 
metástasis. 
 
